KR20210150831A - Cosmetics using aloe extract effective for preventing atopic dermatitis - Google Patents

Cosmetics using aloe extract effective for preventing atopic dermatitis Download PDF

Info

Publication number
KR20210150831A
KR20210150831A KR1020200067725A KR20200067725A KR20210150831A KR 20210150831 A KR20210150831 A KR 20210150831A KR 1020200067725 A KR1020200067725 A KR 1020200067725A KR 20200067725 A KR20200067725 A KR 20200067725A KR 20210150831 A KR20210150831 A KR 20210150831A
Authority
KR
South Korea
Prior art keywords
aloe
extract
fermented
hydrolysis
fermentation
Prior art date
Application number
KR1020200067725A
Other languages
Korean (ko)
Inventor
황선영
Original Assignee
황선영
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 황선영 filed Critical 황선영
Priority to KR1020200067725A priority Critical patent/KR20210150831A/en
Publication of KR20210150831A publication Critical patent/KR20210150831A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/06Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to cosmetics using an aloe extract effective for preventing atopic dermatitis, and more particularly, to a method for preparing a fermented and hydrolyzed aloe extract with an effect of preventing and ameliorating atopic dermatitis and cosmetics prepared by using the same, with an aim at preparing a fermented extract capable of increasing skin penetration of active ingredients and antioxidant activity and enhancing anti-inflammatory and anti-allergic effects by extracting and fermenting aloe. To this end, the method for preparing a fermented aloe extract with an effect of preventing and ameliorating atopic dermatitis according to the present invention comprises the steps of: taking 1.0 kg of aloe shell, adding 2 liters (L) of ethanol (EtOH), and leaving at 50 to 60℃ for 8 hours while occasionally shaking; filtering the ethanol extracted solution under reduced pressure by using filter paper while shaking, and taking the filtrate; putting the filtrated liquid in a vacuum concentrator and concentrating under reduced pressure at 50 to 60℃ under constant conditions so as to make a soft extract; and dissolving 50,000 units of β-glucosidase in 10 milliliters of water, adding to the soft extract, and reacting at 40 to 50℃ for 8 hours while shaking so as to ferment and hydrolyze.

Description

아토피 피부염 예방에 효과적인 알로에 추출물을 이용한 화장품{Cosmetics using aloe extract effective for preventing atopic dermatitis}Cosmetics using aloe extract effective for preventing atopic dermatitis

본 발명은 아토피 피부염 예방에 효과적인 알로에 추출물을 이용한 화장품에 관한 것으로서, 보다 상세하게는 알로에를 추출 및 발효시킴으로서 유효성분의 피부침투력 및 항산화활성을 높이고, 항염 및 항알러지 효능을 증진시킬 수 있는 발효추출물을 제조하고, 이를 함유한 화장품을 개발하기 위한 목적으로 아토피 피부염 예방 및 개선효과를 나타내는 알로에 발효 및 가수분해 추출물의 제조방법 및 이를 이용하여 제조된 화장품에 관한 것이다.The present invention relates to a cosmetic using an aloe extract effective for preventing atopic dermatitis, and more particularly, by extracting and fermenting aloe to increase skin penetration and antioxidant activity of active ingredients, and to enhance anti-inflammatory and anti-allergic effects. , and relates to a method for producing a fermented and hydrolyzed aloe extract showing atopic dermatitis prevention and improvement effects for the purpose of developing cosmetics containing the same, and to cosmetics manufactured using the same.

알로에는 백합과(Liliaceae)에 속하는 알로에속의 다년생 열대식물로서 원산지는 주로 아프리카이며 현재 600여종이 세계 각지에 분포 또는 재배되고 있다. 우리나라에서 주로 재배되고 있는 알로에는 알로에 베라(A. barbadensis Mill.)와 알로에 아보레센스(A. arborescens Mill.), 알로에 사포나리아(A. saponaria Haw.) 등이다. 알로에는 오래전부터 민간약으로 사용되기 시작하여 주로 고미 건위 및 완하제로 이용되어 왔다. 모두 정도의 차이는 있으나 항염증작용, 항궤양 및 세포재생작용, 항균 및 항진균작용, 항바이러스작용, 혈당개선작용, 위액분비억제작용, 간세포보호작용, 사하작용, 면역조절작용, 항암작용 등을 가지고 있다.Aloe is a perennial tropical plant of the genus Aloe belonging to the Liliaceae family. Aloe vera (A. barbadensis Mill.), Aloe arborescens Mill., Aloe saponaria Haw., etc. are mainly cultivated in Korea. Aloe has been used as a folk medicine for a long time and has been mainly used as a bitter taste and laxative. All have different degrees of action, but have anti-inflammatory action, anti-ulcer and cell regeneration action, antibacterial and antifungal action, antiviral action, blood sugar improvement action, gastric secretion inhibitory action, hepatocellular protection action, sacrificial action, immunomodulatory action, anticancer action, etc. Have.

알로에가 가장 많이 활용되고 있는 분야는 화장품으로써 피부보습 기능이 뛰어나고 항염작용, 항알러지작용, 항산화작용 및 피부 연화작용이 탁월하여 어린이로부터 노인에 이르기까지 다양한 층에서 쓰이고 있다.The field where aloe is most widely used is as a cosmetic product. It has excellent skin moisturizing properties, and has excellent anti-inflammatory, anti-allergic, antioxidant and skin softening properties, so it is used in various layers from children to the elderly.

특히 아토피 피부염은 만성질환으로써 화장품 종류에 따라 민감한 반응을 나타내기 때문에 알로에 추출물을 아토피 피부염에 사용하기위한 연구가 끊임없이 이어져 왔다.In particular, atopic dermatitis is a chronic disease, and since it shows a sensitive reaction depending on the type of cosmetics, research to use aloe extract for atopic dermatitis has been continuously conducted.

아토피 피부염 (Atopic dermatisis, AD)은 소양감을 동반하는 만성 재발성 피부질환으로 약 50%의 환자에서 1세 이전에 시작되며 30%정도가 1세에서 5세 사이에 발병하는 것으로 알려져 있다. 아직까지 아토피 피부염의 기전은 완전히 밝혀지지 않았지만, 단순포진이나 종두증과 같은 바이러스 감염에 대한 취약성과 특정 미생물 항원에 대한 지연형 면역 반응의 감소, IgE의 생산 증가, 접촉 알레르겐에 대한 감수성 감소, 분열 촉진제와 항원에 대한 임파구의 반응 감소, 과립구와 단핵구의 화학주성 감소 등 여러 가지 면역학적인 이상 소견들이 보고되어 있다. 또한, 이 질환의 유병율과 난치성 성인 아토피 피부염으로의 진행이 산업화 된 사회에서 점차 증가하는 추세에 있으며, 이는 아토피 피부염의 발생에 유전적 요인과 함께 산업화와 같은 환경적인 요인이 중요하다는 근거가 된다. 이 질환의 특징은 소양증, 가려움, 태선화, 발진, 인설, 전신 건조 등의 증상이 나타나는 것으로 알려져 있다.Atopic dermatitis (AD) is a chronic recurrent skin disease accompanied by pruritus, and it is known that about 50% of patients begin before 1 year of age, and about 30% develop between 1 and 5 years of age. Although the mechanism of atopic dermatitis has not been fully elucidated, susceptibility to viral infections such as herpes simplex or papillomatosis, decreased delayed immune response to specific microbial antigens, increased IgE production, decreased susceptibility to contact allergens, and fragmentation Various immunological abnormalities have been reported, such as decreased lymphocyte response to promoters and antigens, and decreased chemotaxis of granulocytes and monocytes. In addition, the prevalence of this disease and the progression to intractable adult atopic dermatitis are gradually increasing in the industrialized society, which is the basis for the importance of environmental factors such as industrialization as well as genetic factors in the occurrence of atopic dermatitis. It is known that symptoms such as pruritus, itchiness, lichenification, rash, scale, and body dryness are characteristic of this disease.

아토피 피부염의 치료는 피부염에 대한 기본적인 방법과 유발인자를 규명하여 제거하는 방법들이 적용되고 있다. 일반적으로 병원에서 아토피 피부염 환자의 치료에는 스테로이드제, 타크로리무스나 피메크로니무스와 같은 칼시뉴린(calcineurin) 억제제, 항히스타민제, 시클로스포린(cyclosporin), 메토트렉세이트(methotrexate) 및 아자치오프린(azathioprine)과 같은 면역억제제 등의 약제가 사용되고 있다. 국소 스테로이드제는 병변이 급성으로 악화될 때 증상을 신속하고 효과적으로 호전시킬 수 있으나, 지속적으로 사용 시 부신억제를 유발할 수 있으며 피부위축, 모세혈관 확장, 색소침착 저하, 스테로이드성 여드름, 다모증, 성장장애 등의 우려가 있어 단기간 사용과 표피가 얇거나 혈관이 많은 부위 등 민감한 피부에는 사용하는데 제한이 있다.For the treatment of atopic dermatitis, basic methods for dermatitis and methods to identify and remove triggers are applied. In general, the treatment of atopic dermatitis patients in hospitals includes steroids, calcineurin inhibitors such as tacrolimus or pimecronimus, antihistamines, cyclosporin, methotrexate, and azathioprine. Drugs such as immunosuppressants are used. Topical steroids can relieve symptoms quickly and effectively when the lesion is acutely aggravated, but when used continuously, it can cause adrenal suppression, skin atrophy, capillary dilatation, reduced pigmentation, steroid acne, hirsutism, and growth disorders. There are concerns about such as short-term use and limited use for sensitive skin such as areas with thin epidermis or a lot of blood vessels.

칼시뉴린(Calcineurin)억제제의 경우 기존 치료에 보조적으로 사용할 수 있을 뿐 아니라 국소스테로이드제의 사용으로 인해 발생할 수 있는 문제점을 최소화하여 스테로이드성 내성환자, 눈이나 얼굴, 생식기 주변 등의 피부가 연약한 부위에 적용이 가능하나 2차 치료제로서 2세 이상 소아에서 단기간 사용에 한하여 허가되어 사용되고 있다.In the case of calcineurin inhibitors, they can be used as an adjunct to existing treatments and minimize the problems that may arise from the use of topical steroids. It can be applied, but it is approved and used only for short-term use in children over 2 years of age as a second-line treatment.

아토피 치료용 약제를 사용하면서 장기적인 안목으로 아토피 예방 및 개선에 도움이 되는 화장품의 개발이 필요하다고 볼 수 있다.It can be seen that it is necessary to develop cosmetics that help prevent and improve atopy from a long-term perspective while using drugs for atopy treatment.

본 발명은 이러한 문제점을 해결하기 위하여 안출된 것으로서, 본 발명의 목적은 아토피성 피부에 부작용을 나타내지 않으면서 장기간 사용 시 아토피 예방 및 개선에 도움을 주는 화장품의 개발에 관한 것이며, 피부알러지, 소양증, 접촉성 피부염, 미생물에 의한 피부염증, 피부발진 및 아토피질환으로부터 손상된 피부를 보호하고 예방하며 개선하기 위하여, 알로에 추출물에 효소를 가하여 발효 및 가수분해시키고, 여기에 황금 발효추출물, 어성초 발효추출물 등을 복합하여 바디로션, 바디클린저, 페이셜크림 및 바디크림 등 다양한 종류의 화장품을 개발하는데 그 목적이 있다.The present invention has been devised to solve these problems, and an object of the present invention relates to the development of cosmetics that help prevent and improve atopic dermatitis when used for a long period of time without showing side effects on atopic skin, skin allergies, pruritus, In order to protect, prevent and improve damaged skin from contact dermatitis, skin inflammation caused by microorganisms, skin rash and atopic diseases, enzymes are added to aloe extract to ferment and hydrolyze, and golden fermented extract, fermented eosin-chief extract, etc. The purpose is to develop various types of cosmetics such as body lotion, body cleanser, facial cream and body cream by combining them.

상술한 목적을 달성하기 위한 본 발명에 따른 아토피 피부염 예방 및 개선효과를 나타내는 알로에 발효추출물의 제조방법은, 알로에 껍질 1.0kg을 취하고 에탄올(EtOH) 2리터(L)를 넣어 50 ~ 60℃에서 8시간동안 가끔씩 흔들어 주면서 방치하는 단계;In the method for producing a fermented aloe extract exhibiting an effect of preventing and improving atopic dermatitis according to the present invention for achieving the above object, 1.0 kg of aloe peel is taken and 2 liters (L) of ethanol (EtOH) is added, followed by 8 at 50 to 60 ° C. A step of leaving it to stand while shaking occasionally for a period of time;

에탄올 추출용액을 흔들어 주면서 여과지를 사용하여 감압으로 하여 여과하고 여액을 취하여 단계;Filtering under reduced pressure using filter paper while shaking the ethanol extraction solution, and taking the filtrate;

여과한 액을 감압농축기에 넣고 50 ~ 60℃에서 일정한 조건으로 감압 농축시켜 연조엑스 상태로 만드는 단계;Putting the filtrated liquid in a vacuum concentrator and concentrating under a reduced pressure at 50 ~ 60 ℃ under constant conditions to make a soft joe extract;

베타글루코시다제(β-glucosidase) 50,000unit를 10밀리리터의 물에 녹여 연조엑스에 가하고, 40 ~ 50℃에서 8시간 동안 흔들어 주면서 반응시켜 빌효 및 가수분해시키는 단계로 이루어진 것을 특징으로 한다.Dissolving 50,000 units of beta-glucosidase in 10 milliliters of water, adding it to soft extract, and shaking it for 8 hours at 40-50° C.

또한, 본 발명에 따른 알로에 발효추출물을 이용하여 제조되는 화장품은, 상기 알로에 발효 및 가수분해 추출물 100g을 취하고, 황금 가수분해 추출물 200g, 어성초 발효추출물 100g 및 알로에베라 20kg을 균일하게 혼합하여 알로에 발효 및가수분해 추출 복합물을 얻은 다음, 정제수 40kg, 글리세릴스테아레이트 6kg, 피이지100스테아레이트 4kg, 소르비탄스테아레이트 3kg, 폴리소르베이트20 3kg, 디메치콘 0.5kg, 트리에탄올아민 1kg, 카프릴릭카프릴트리글리세라이드 4kg, 카보머941 1kg, 부틸렌글라이콜 1kg, 이소도데칸 0.5kg, 글리세린 5kg, 디에칠헥실카보네이트 3kg, 디카프릴카보네이트 3kg, 스테아릴알코올 5kg, 글리세릴베헤네이트 1kg, 페녹시에탄올 0.5kg, 디스테아디모늄헥토라이트 1kg, 소르비탄세스퀴올레이이트 3kg, 메칠파라벤 0.3kg, 프로필파라벤 0.2kg, 디소디움이디티에이 0.5kg을 혼합하고 70 ~ 75℃에서 4시간 동안 가온하면서 혼합하여 바디로션 기제를 조제한 후 상기 알로에 가수분해 추출 혼합물과 함께 호모게나이저에 투입하여 3,000 ~ 3,500 알피엠으로 30분 동안 균질화시켜 바디로션을 제조하는 것을 특징으로 한다.In addition, cosmetics produced using the fermented aloe extract according to the present invention take 100 g of the aloe fermented and hydrolyzed extract, and uniformly mix 200 g of hydrolyzed golden extract, 100 g of fermented eoseongcho ferment extract and 20 kg of aloe vera to ferment aloe and After obtaining the hydrolysis-extraction complex, purified water 40 kg, glyceryl stearate 6 kg, PEG 100 stearate 4 kg, sorbitan stearate 3 kg, polysorbate 20 3 kg, dimethicone 0.5 kg, triethanolamine 1 kg, caprylic caprylic triglyceride ceride 4kg, carbomer 941 1kg, butylene glycol 1kg, isododecane 0.5kg, glycerin 5kg, diethylhexyl carbonate 3kg, dicapryl carbonate 3kg, stearyl alcohol 5kg, glyceryl behenate 1kg, phenoxyethanol 0.5kg , Disteadimonium hectorite 1kg, sorbitan sesquioleate 3kg, methylparaben 0.3kg, propylparaben 0.2kg, disodiumEDTA 0.5kg, mixed and heated at 70 ~ 75℃ for 4 hours After preparing the lotion base, it is introduced into a homogenizer together with the aloe hydrolysis extraction mixture and homogenized at 3,000 to 3,500 RPM for 30 minutes to prepare a body lotion.

또한, 상기 알로에 발효 및 가수분해 추출물 100g을 취하고, 황금 가수분해 추출물 200g, 어성초 발효추출물 100g 및 알로에베라 20kg을 균일하게 혼합하여 알로에 발효 및가수분해 추출 복합물을 얻은 다음, 정제수 50kg, 라우린산 6kg, 미리스틴산 4kg, 모노알킬포스페이트 1kg, 옥시벤존 0.5kg, 글리콜디스테아레이트 4kg, 트리에탄올아민 1kg, 폴리쿠아테니움 1kg, 라우릴설폰산트리에탄올아민 1kg, 라우라마이드 DEA 1kg, 사이클로메치콘 0.5kg, 코카미드프로필베타인 2kg, K-쿠일가수분해콜라겐 1kg, 부틸렌글라이콜 1kg, 피이지-7-글리세릴코코에이트 5kg, 글리세린 5kg, 글리세릴베헤네이트 1kg, 페녹시에탄올 1kg, 디메치콘 0.5kg, 소르비탄세스퀴올레이이트 3kg, 프로필렌카보네이트 1kg, 메칠파라벤 0.3kg, 프로필파라벤 0.2kg, 디소디움이디티에이 0.5kg을 혼합하고, 70 ~ 75℃에서 4시간 동안 가온하면서 혼합하여 바디클린저 기제를 조제한 후 상기 알로에 발효 및 가수분해 추출 복합물과 함께 호모게나이저에 투입하여 3,000 ~ 3,500 알피엠으로 30분 동안 균질화시켜 바디클린저로 제조하는 것을 특징으로 한다.In addition, 100 g of the aloe fermented and hydrolyzed extract was taken, and 200 g of golden hydrolyzed extract, 100 g of fermented fish extract and 20 kg of aloe vera were uniformly mixed to obtain an aloe fermented and hydrolyzed extract complex, followed by purified water 50 kg, lauric acid 6 kg , myristic acid 4kg, monoalkylphosphate 1kg, oxybenzone 0.5kg, glycol distearate 4kg, triethanolamine 1kg, polyquatenium 1kg, laurylsulfonic acid triethanolamine 1kg, lauramide DEA 1kg, cyclomethicone 0.5kg , cocamide propylbetaine 2kg, K-Quyl hydrolyzed collagen 1kg, butylene glycol 1kg, PEG-7-glyceryl cocoate 5kg, glycerin 5kg, glyceryl behenate 1kg, phenoxyethanol 1kg, dimethicone 0.5 kg, sorbitan sesquioleate 3kg, propylene carbonate 1kg, methylparaben 0.3kg, propylparaben 0.2kg, disodium EDTA 0.5kg, mixed while heating at 70 ~ 75℃ for 4 hours to form a body cleanser base After preparing the aloe fermentation and hydrolysis extraction complex, it is put into a homogenizer and homogenized at 3,000 to 3,500 RPM for 30 minutes to prepare a body cleanser.

또한, 상기 알로에 발효 및 가수분해 추출물 100g을 취하고, 황금 가수분해 추출물 200g, 어성초 발효추출물 100g 및 알로에베라 20kg을 균일하게 혼합하여 알로에 발효 및가수분해 추출 복합물을 얻은 다음, 정제수 35kg, 글리세릴스테아레이트 5kg, 피이지100스테아레이트 3kg, 소르비탄스테아레이트 4kg, 폴리소르베이트20 3kg, 디메치콘 1kg, 트리에탄올아민 1kg, 화이트비스왁스 2kg, 카보머941 1kg, 부틸렌글라이콜 0.5kg, 이소도데칸 1kg, 글리세린 5kg, 디에칠헥실카보네이트 1kg, 디카프릴카보네이트 1kg, 스테아릴알코올 4kg, 글리세릴베헤네이트 1kg, 페녹시에탄올 1kg, 디스테아디모늄헥토라이트 1kg, 소르비탄세스퀴올레이이트 2kg, 메칠파라벤 0.3kg, 프로필파라벤 0.2kg, 디소디움이디티에이 0.5kg을 혼합하고, 70 ~ 75℃에서 4시간 동안 가온하면서 혼합하여 페이셜크림 기제를 조제한 후 상기 알로에 발효 및 가수분해 추출 복합물과 함께 호모게나이저에 투입하여 3,000 ~ 3,500 알피엠으로 30분 동안 균질화시켜 페이셜크림으로 제조하는 것을 특징으로 한다.In addition, 100 g of the aloe fermented and hydrolyzed extract was taken, and 200 g of golden hydrolyzed extract, 100 g of fermented eoseongcho ferment extract and 20 kg of aloe vera were uniformly mixed to obtain an aloe fermented and hydrolyzed extract, followed by purified water 35 kg, glyceryl stearate 5kg, PEG 100 Stearate 3kg, Sorbitan Stearate 4kg, Polysorbate 20 3kg, Dimethicone 1kg, Triethanolamine 1kg, White Beeswax 2kg, Carbomer 941 1kg, Butylene Glycol 0.5kg, Isododecane 1kg , glycerin 5kg, diethylhexyl carbonate 1kg, dicapryl carbonate 1kg, stearyl alcohol 4kg, glyceryl behenate 1kg, phenoxyethanol 1kg, disteadimonium hectorite 1kg, sorbitan sesquioleate 2kg, methylparaben 0.3 kg, 0.2 kg of propylparaben, and 0.5 kg of disodium EDTA were mixed and mixed while heating at 70 to 75° C. for 4 hours to prepare a facial cream base, and then to the homogenizer together with the aloe fermentation and hydrolysis extraction complex It is characterized in that it is added and homogenized for 30 minutes at 3,000 to 3,500 RPM to prepare a facial cream.

또한, 상기 알로에 발효 및 가수분해 추출물 100g을 취하고, 황금 가수분해 추출물 200g, 어성초 발효추출물 100g 및 알로에베라 20kg을 균일하게 혼합하여 알로에 발효 및가수분해 추출 복합물을 얻은 다음, 정제수 40kg, 스쿠알란 1kg, 세티아릴알코올 1kg, 마카다미아씨 오일 1kg, 포도씨 오일 0.5kg, 부틸렌글라이콜 1kg, 폴리글타믹애씨드 1kg, 글리세린 5kg, 디에칠헥실카보네이트 1kg, 디카프릴카보네이트 0.5kg, 스테아릭애씨드 3kg, 카프릴릭/카프릭 트리글리세라이드 1kg, 스테아릴알코올 1kg, 페녹시에탄올 0.5kg, 녹차씨오일 0.5kg, 아라카딜알코올 0.4kg, 베헤닐알코올 0.3kg, 아라카딜 글루코사이드 0.3kg, 세틸팔미테이트 0.2kg, 소르비탄올리베이트 0.5kg, 소르비탄 팔미테이트 1kg, 세테아릴 올리베이트 0.5kg, 피이지-32 0.2kg, 세라마이드-3 0.3kg, 디메치콘 0.5kg, 알란토인 0.2kg, 카보머 940 0.5kg 및 트리에탄올아민 0.1kg을 혼합하고, 70 ~ 75℃에서 4시간 동안 가온하면서 혼합하여 바디크림 기제를 조제한 후 상기 알로에 발효 및 가수분해 추출 복합물과 함께 호모게나이저에 투입하여 3,000 ~ 3,500 알피엠으로 30분 동안 균질화시켜 바디크림을 제조하는 것을 특징으로 한다.In addition, 100 g of the aloe fermented and hydrolyzed extract was taken, and 200 g of golden hydrolyzed extract, 100 g of fermented fish extract and 20 kg of aloe vera were uniformly mixed to obtain an aloe fermentation and hydrolysis extraction complex, and then purified water 40 kg, squalane 1 kg, ceti Aryl alcohol 1kg, macadamia seed oil 1kg, grape seed oil 0.5kg, butylene glycol 1kg, polyglutamic acid 1kg, glycerin 5kg, diethylhexyl carbonate 1kg, dicapryl carbonate 0.5kg, stearic acid 3kg, caprylic/ Capric triglyceride 1kg, stearyl alcohol 1kg, phenoxyethanol 0.5kg, green tea seed oil 0.5kg, aracadyl alcohol 0.4kg, behenyl alcohol 0.3kg, aracadyl glucoside 0.3kg, cetyl palmitate 0.2kg, sorbitanol Bate 0.5kg, Sorbitan Palmitate 1kg, Cetearyl Oliveate 0.5kg, PEG-32 0.2kg, Ceramide-3 0.3kg, Dimethicone 0.5kg, Allantoin 0.2kg, Carbomer 940 0.5kg and Triethanolamine 0.1kg After preparing the body cream base by mixing while warming at 70 to 75° C. for 4 hours, it is put into a homogenizer together with the aloe fermentation and hydrolysis extraction complex, and homogenized with 3,000 to 3,500 RPM for 30 minutes to create a body cream characterized in that it is manufactured.

본 발명의 또 다른 목적 및 효과는 이하의 상세한 설명으로부터 명확하게 되고, 본 발명의 바람직한 실시예를 나타내는 상세한 설명 및 실시예는 본 발명의 범주를 제한하는 것이 아니다.Other objects and effects of the present invention will become apparent from the following detailed description, and the detailed description and examples indicating preferred embodiments of the present invention do not limit the scope of the present invention.

본 발명에 따른 아토피 피부염 예방에 효과적인 알로에 추출물을 이용한 화장품에 의하면, 접촉성 피부염, 미생물에 의한 피부염증, 피부 알러지, 소양증, 피부발진 및 아토피 질환으로부터 손상된 피부를 보호하고 예방하며 개선하기 위하여, 알로에 발효 및 가수분해 추출물에 황금 가수분해 추출물, 어성초 벌효추출물, 알로에베라 등을 복합하여 바디로션, 바디클린저, 페이셜크림 및 바디크림 등 다양한 종류의 화장품을 개발한 결과 피부에 대한 침투력이 강하고 높은 항산화작용과 함께 그람양성 및 음성균에 대한 항균력이 높고 집먼지 진드기로 유발된 마우스의 아토피에 대하여 양호한 예방 및 개선 효과를 나타낸다.According to the cosmetic using the aloe extract effective for preventing atopic dermatitis according to the present invention, in order to protect, prevent and improve damaged skin from contact dermatitis, skin inflammation caused by microorganisms, skin allergy, pruritus, skin rash, and atopic diseases, aloe As a result of developing various types of cosmetics such as body lotion, body cleanser, facial cream, and body cream by combining fermented and hydrolyzed extract with golden hydrolyzed extract, eoseongcho bee extract, and aloe vera, it has strong penetration into the skin and high antioxidant activity. It has high antibacterial activity against Gram-positive and negative bacteria and shows good prevention and improvement effects on atopy in mice induced by house dust mites.

이하, 본 발명에 따른 하나의 바람직한 실시예를 상세히 설명한다.Hereinafter, one preferred embodiment according to the present invention will be described in detail.

상술한 목적을 달성하기 위하여 본 발명에 주요성분으로 적용되는 알로에는 백합과(Liliaceae)에 속하는 알로에 속의 다년생 열대 식물로서 원산지는 주로 아프리카이며 현재 600여종이 세계 각지에 분포 또는 재배되고 있다.In order to achieve the above object, aloe applied as a main ingredient in the present invention is a perennial tropical plant of the genus Aloe belonging to the Liliaceae family.

우리나라에서 주로 재배되고 있는 알로에는 알로에 베라(A. barbadensis Mill.)와 알로에 아보레센스(A. arborescens Mill.), 알로에 사포나리아(A. saponaria Haw.) 등이다.Aloe vera (A. barbadensis Mill.), Aloe arborescens Mill., Aloe saponaria Haw., etc. are mainly cultivated in Korea.

알로에는 오래전부터 민간약으로 사용되기 시작하여 주로 고미 건위 및 완하제로 이용되어 왔다. 모두 정도의 차이는 있으나 항염증작용, 항궤양 및 세포재생작용, 항균 및 항진균작용, 항바이러스작용, 혈당개선작용, 위액분비억제작용, 간세포보호작용, 사하작용, 면역조절작용, 항암작용 등을 가지고 있는 것으로 알려저 있다.Aloe has been used as a folk medicine for a long time and has been mainly used as a bitter taste and laxative. All have different degrees of action, but have anti-inflammatory action, anti-ulcer and cell regeneration action, antibacterial and antifungal action, antiviral action, blood sugar improvement action, gastric secretion inhibitory action, hepatocellular protection action, sacrificial action, immunomodulatory action, anticancer action, etc. It is known to have

알로에 중에 함유되어 있는 유효성분으로는 barbaloin, aloesin, aloenin, isobarbaloin, isoaloeresin, aloeemodin 등이 보고되어 있다.As active ingredients contained in aloe, barbaloin, aloesin, aloenin, isobarbaloin, isoaloeresin, and aloeemodin have been reported.

알로에베라 추출물에 대한 약리활성에 관한 연구로는 알로에 추출물이 carrageenan으로 유발된 흰쥐의 족부종에 대하여 뚜렷한 억제효과를 나타내고 시험관 내 실험(in vitro)에서 PGE2의 생성을 억제시켰다고 발표된 바 있으며, 인체 직장점막에 대한 알로에 베라 겔의 항염효과에 대한 연구로서 알로에를 투여하였을 때 PGE2의 생성을 억제시킴으로써 항염효과를 나타내는 것으로 보고되어 있다.A study on the pharmacological activity of aloe vera extract showed that aloe extract showed a distinct inhibitory effect on carrageenan-induced foot edema in rats and inhibited the production of PGE 2 in vitro. As a study on the anti-inflammatory effect of aloe vera gel on the human rectal mucosa, it is reported that when aloe is administered, it suppresses the production of PGE 2 and thus exhibits an anti-inflammatory effect.

알로에베라 겔의 마우스에 대한 면역조절작용 연구로는 알로에베라 추출물을 투여 시 항체생성을 촉진시키고 반점형성세포(plaque forming cell)의 수를 증가시킨다고 보고되어 있고, 알로에베라에 함유된 다당류의 면역조절에 대한 화학적 특성에 대한 연구에서는 알로에 중에 함유된 다당류성분들을 효소 및 산 가수분해를 통하여 구조적 특성을 규명한바 있다.As a study on the immunomodulatory effect of Aloe vera gel on mice, it has been reported that when Aloe vera extract is administered, it promotes antibody production and increases the number of plaque forming cells. Immunomodulation of polysaccharides contained in Aloe vera In a study on the chemical properties of aloe, the structural characteristics of polysaccharide components contained in aloe were identified through enzymatic and acid hydrolysis.

알로에의 활성성분으로 알려져 있는 barbaloin, aloesin, aloenin, aloe-emodin 등은 주로 알로에 식물의 껍질에 다량 함유되어 있으므로 본 발명에 사용된 알로에 식물의 사용부위는 주로 껍질의 추출물을 발효 및 가수분해 시킨다음 여기에 알로에 베라를 혼합하였다.Barbaloin, aloesin, aloenin, aloe-emodin, which are known as active ingredients of aloe, are mainly contained in the bark of the aloe plant. Aloe vera was mixed here.

알로에와 함께 복합성분으로 함유되어 있는 황금 (Scutellaria Radix)은 꿀풀과 (Labiatae)에 속하는 다년생 초본식물인 속썩은 풀 (Scutellaria baicalensis GEORGI)의 주피를 벗긴 뿌리로 한방에서는 청열, 해독, 담즙배설촉진, 항균, 이뇨, 완하, 죽상동맥경화 방지, 위액분비 억제, 진정, 혈압강하 작용 등의 목적으로 사용되어 왔다.Golden (Scutellaria Radix), which is contained as a complex ingredient together with aloe, is the root of Scutellaria baicalensis GEORGI, a perennial herbaceous plant belonging to the Lamiaceae family. It has been used for antibacterial, diuretic, laxative, atherosclerotic prevention, gastric juice suppression, sedation, and blood pressure lowering effects.

황금의 활성성분은 바이칼린(Baicalin), 바이칼레인(Baicalein) 및 우고닌(Wogonine) 등으로서 약리작용에 대한 연구로는, 흰쥐의 간에서 지질산화작용을 억제함으로써 혈청 중 중성지방과 유리지방산의 함유량을 감소시키고 에탄올(EtOH) 섭취에 의해 유발된 고지혈증에 효과가 있음이 알려졌고, 또한 황금성분의 항산화 작용으로 산화에 의한 세포손상을 보호하고 활성산소 및 프리 레디컬(Free radical))에 의한 피부세포의 산화 및 손상을 방지하는 것으로 보고된 바 있다.The active ingredients of gold are baicalin, baicalein, and wogonine, etc., and the study on the pharmacological action shows that by inhibiting lipid oxidation in the liver of rats, It is known that the content is reduced and is effective in hyperlipidemia induced by ethanol (EtOH) ingestion. In addition, the antioxidant action of golden ingredient protects the skin from cellular damage caused by oxidation and protects the skin from free radicals and free radicals. It has been reported to prevent cell oxidation and damage.

황금의 주성분인 바이칼린(Baicalin)은 플라보노이드 구조를 가지고 있고 항알러지, 항박테리아 및 항바이러스와 같은 다양한 생물학적 활성을 가지며, 그밖에 리포옥시지나제(lipoxygenase)의 저해, 마이크로솜의 지질 과산화반응 억제, 산소라디칼 생성의 저해, 그리고 최근 활성 산소종(H2O2, -OH 및 O2 -) 으로 유도된 섬유아세포 손상의 억제 등의 항산화 활성이 보고되어 있다.Baicalin, the main component of gold, has a flavonoid structure and has various biological activities such as anti-allergy, antibacterial and antiviral, and in addition, inhibition of lipoxygenase, inhibition of microsome lipid peroxidation, Antioxidant activity such as inhibition of oxygen radical production, and inhibition of fibroblast damage induced by reactive oxygen species (H 2 O 2 , —OH and O 2 —) has recently been reported.

황금 중에 가장 함유량이 높은 바이칼린은 인체 및 동물의 대장균(E. coli)이 분비하는 베타 글루쿠로니다제(β-glucuronidase)에 의하여 가수분해되어 바이칼레인을 생성하면서 항산화활성, 항염효과, 항알러지효과, 피부손상 억제효과가 현저하게 증강되는 것으로 보고되어 있다.Baicalin, which has the highest content in gold, is hydrolyzed by beta-glucuronidase secreted by E. coli in humans and animals to produce baicalin, with antioxidant activity, anti-inflammatory effect, and anti-inflammatory properties. It has been reported that the allergy effect and the skin damage suppression effect are remarkably enhanced.

또한, 어성초(Houttuynia cordata)는 삼백초과(Saururaceae)에 속하는 다년생 초본식물로 줄기는 가늘고 붉은 보랏빛을 띄며 잎은 심장모양이고 끝이 뾰족하며, 잎은 고구마나 메밀잎과 비슷하며, 잎과 줄기의 즙액에서 “생선비린내”와 매우 유사한 냄새가 있어 어성초(魚腥草)라 불리게 되었다. 어성초는 이뇨, 진통, 지혈, 조직재생, 혈관확장 및 지해작용을 하며, 본초강목, 동의보감, 식물학대사전에는 사열, 매독, 종기, 백독, 치질, 탈항에 효력이 있고 중금속 독을 없애준다고 하였다.In addition, Houttuynia cordata is a perennial herbaceous plant belonging to the Saururaceae family. The stem is thin and reddish-purple, the leaves are heart-shaped and pointed, and the leaves are similar to sweet potatoes or buckwheat leaves, and the juice of the leaves and stems. It has a smell very similar to the “fishy smell” of fish, so it was called Eoseongcho (魚腥草). Eoseongcho has diuretic, analgesic, hemostasis, tissue regeneration, vasodilation and antidiarrheal action, and in the herbal remedies, donguibogam, botanical dictionary, it is said that it is effective in diarrhoea, syphilis, boil, white poison, hemorrhoids, prolapse and eliminates heavy metal poison.

어성초의 약용성, 식용성 제고를 위한 기능성분 분리 및 이용기술의 연구 결과 어성초의 flavonoid 성분으로 quercetin, quercitrin, rutin 및 myricetin 등이 확인되어 있고 이들 성분 중 quercetin은 양파에도 함유되어 있는 것으로 알려져 있다.As a result of a study on the separation and utilization technology of functional ingredients to improve medicinal properties and edibility of eoseongcho, quercetin, quercitrin, rutin and myricetin were identified as flavonoids of eoseongcho, and among these ingredients, quercetin is known to be contained in onions.

어성초 및 양파에 함유되어 있는 quercetin 및 quercetin glycosides의 구조적 특성에 관한 연구 결과 이들 페놀성 화합물이 발암성 물질의 활성감소, 변이 암세포의 생육저해, 혈압 강하, 모세혈관 강화 등의 약리작용을 보고되어 있으며, quercetin의 약리작용으로는 과산화지질 형성 억제작용, 항바이러스, 항균효과, 항돌연변이 작용 등이 알려져 있다.As a result of a study on the structural characteristics of quercetin and quercetin glycosides contained in Ewoongcho and onion, these phenolic compounds reported pharmacological actions such as reduction of carcinogenic activity, inhibition of growth of mutant cancer cells, lowering of blood pressure, and strengthening of capillaries. , quercetin has known pharmacological actions such as inhibition of lipid peroxide formation, antiviral, antibacterial, and antimutagenic action.

따라서 본 발명은 화장품제제의 주성분으로서 알로에 발효 및 가수분해추출물에 황금 가수분해 추출물, 어성초발효추출물 및 알로에베라를 복합시킴으로써 항산화작용과 함께 항염, 항알러지, 소양억제, 접촉성 피부염 개선과 함께 항아토피효과를 증강시킬 수 있고, 어린이 및 유아의 피부에도 자극과 손상을 주지 않으며 독성이 없고 자극이 적은 안전한 기제를 사용함으로써 여성 및 민감성 피부에도 전혀 거부반응을 나타내지 않고, 피부보습과 유연성을 유지하면서 피부노화를 지연시킬 수 있는 처방을 구성하여 바디로션, 바디클린저, 페이셜크림 및 바디로션 등의 제제를 개발하였다.Accordingly, the present invention provides anti-inflammatory, anti-allergic, pruritus suppression, contact dermatitis improvement and anti-atopic dermatitis along with antioxidant action by combining golden hydrolyzed extract, fermented fish extract and aloe vera with aloe fermented and hydrolyzed extract as the main component of cosmetic preparations. It can enhance the effect, does not irritate or damage the skin of children and infants, and by using a safe, non-toxic and less irritating base, it does not show any rejection reaction even for women and sensitive skin, and it does not cause skin aging while maintaining skin moisture and flexibility. We developed formulations such as body lotion, body cleanser, facial cream and body lotion by formulating a prescription that can delay

상기의 목적을 달성하기 위한 본 발명의 특징은 아래와 같으며, 구성비율은 본원 발명에 해당되는 것이고, 구성량에 대해서는 ± 10% 범위에서 실시가 가능하다.The features of the present invention for achieving the above object are as follows, and the composition ratio corresponds to the present invention, and the composition amount can be implemented in the range of ± 10%.

이하 본 발명에 따른 혼합물 또는 조성물의 작용 및 실험결과에 대해 설명한다.Hereinafter, the action and experimental results of the mixture or composition according to the present invention will be described.

1. 알로에 가수분해물 히드로겔의 제조1. Preparation of aloe hydrolyzate hydrogel

알로에 1㎏을 절개한 후 껍질과 황색 내피 분비물질을 취하고 50℃에서 3일간 통풍 건조시킨 다음 에탄올 600㎖ 를 넣고 60℃ 수욕상에서 6시간동안 진탕 추출하여 여과하였다. 여액을 감압 농축 후 동결 건조하여 알로에의 갈색 분말 (수율 15.4 %)을 얻어 시료로 사용하였다.After 1 kg of aloe was incised, the skin and yellow endothelial secretions were taken, air-dried at 50°C for 3 days, then 600 ml of ethanol was added, extracted with shaking in a water bath at 60°C for 6 hours, and filtered. The filtrate was concentrated under reduced pressure and then freeze-dried to obtain a brown powder of aloe (yield: 15.4%), which was used as a sample.

알로에 히드로겔의 제조는 먼저 알로에 엑스 분말을 정제수에 용해시키고 프로필렌글리콜(propylene glycol), 라브라솔(labrosol) 및 에탄올을 순차적으로 가하여 혼합한 후 카르보폴 940(carbopol940)을 넣어 팽윤시키고 트리에탄올아민(triethanolamine)으로 pH 6.5로 조정하여 히드로겔을 제조하였다.For the preparation of aloe hydrogel, first, aloe extract powder is dissolved in purified water, propylene glycol, labrosol and ethanol are sequentially added and mixed, and then Carbopol 940 is added to swell and triethanolamine ( triethanolamine) to prepare a hydrogel by adjusting the pH to 6.5.

알로에 가수분해 히드로겔의 제조(이하 ALH 겔)는 알로에 엑스 분말을 정제수에 용해시키고 베타글루코시다제(β-glucosidase) 1,000단위, 5,000단위를 각각 가하여 50℃에서 4시간 반응시킨 후에 알로에 가수분해물(ALH) 1%, 알로에 가수분해물(ALH) 5%를 제조하였다 (표 1 참조).For the preparation of aloe hydrolyzed hydrogel (hereinafter ALH gel), aloe extract powder was dissolved in purified water, 1,000 units and 5,000 units of beta-glucosidase were added, respectively, and reacted at 50°C for 4 hours. ALH) 1% and aloe hydrolyzate (ALH) 5% (see Table 1).

표 1. 알로에 가수분해물 히드로겔의 제조방법Table 1. Preparation method of aloe hydrolyzate hydrogel

Figure pat00001
Figure pat00001

2. 집먼지 진드기(DPE)를 이용한 피부염 유도 및 시료 처리2. Dermatitis induction and sample processing using house dust mite (DPE)

아토피 피부염의 유발은 8주령 된 Nc/Nga 생쥐의 목, 귀, 등 인접 부위를 깨끗하게 제모한 후 제모가 끝나면 피부의 미세 상처가 치유되도록 24시간 방치시킨 다음 4% SDS 용액을 제모 부위에 분무한 후, 0.5 % 트윈(Tween) 20과 인산완충용액(PBS)으 로 배양액을 만들어 여기에 집먼지 진드기 추출물 (D. pteronyssinus, DPE, 연세대학교 미생물학교실) 항원을 넣어 만든 1% 액을 1주일에 3번씩 8주간 50 ㎕씩 도포하여 아토피 피부염을 유발시켰다. 대조군에는 생리식염수를 적용하였고, 싸이클로스포린 A(cyclosporin A)는 10 ㎍씩 1일 1회 정맥주사로 8주간 투여하였고 알로에 가수분해물(ALH) 1%, 알로에 가수분해물(ALH) 5%는 8주간 피부에 도포하였다.To induce atopic dermatitis, the neck, ears, and back of 8-week-old Nc/Nga mice were cleaned of hair removal and then left for 24 hours to heal micro-wounds on the skin after hair removal was finished, and 4% SDS solution was sprayed onto the hair removal area. Then, make a culture solution with 0.5% Tween 20 and phosphate buffer solution (PBS), and add a 1% solution prepared by adding house dust mite extract (D. Atopic dermatitis was induced by applying 50 μl each for 8 weeks. Physiological saline was applied to the control group, and 10 μg of cyclosporin A was administered intravenously once a day for 8 weeks. It was applied to the skin.

3. 면역 세포수 측정3. Immune Cell Count Measurement

주간 집먼지 진드기(DPE)를 도포하여 피부염이 유발된 마우스의 등 부위 피부조직을 일정량 취하여 잘게 잘라콜라게나제(collagenase) 1 ㎎/㎖ (in 2% FBS + RPMI1640)을 넣고 37℃ 진탕용 (180 rpm, 20 min) 배양기에서 배양한 후 상층액을 회수하는 방법을 4회 반복하였다. 배양된 상층액에 ACK 용액(8.3 g NH4Cl, 1 g KHCO3 in 1 ℓ of demineralized water + 0.1 mM EDTA)을 실온에서 5분 동안 처리하여 적혈구를 용해시키고 다시 D-PBS로 2회 세척한 후 0.04% 트리판블루(trypan blue)로 염색한 후 세포수를 측정하였다. 측정한 피부조직 침윤세포를 5 × 105 세포로 조정한 후 4℃에서 면역 형광염색 (Immunofluorescence staining)을 실시하였다. 각각에 PEanti-CD3e, FITC-anti-CD69, FITC-anti-CCR3, PE-anti-Gr-1, FITC-anti-CD11b, PE-anti-Gr-1, PE-anti-B220 및 FITC-anti-IgE를 넣고 30분간 얼음에서 반응시켰다. 반응 후 3회 이상 인산완충 생리식염수로 세척한 후 플로싸이토미터(flow cytometer)의 Cell Quest 프로그램을 이용하여 CD3+/CD69+, CCR3+, B220+/IgE+, CD11b+/Gr-1+ 세포수를 백분율 (%)로 분석한 후 총세포수를 적용하여 각 조직에서의 절대 세포수 (absolute cell number)를 산출하였다.Take a certain amount of skin tissue from the back of a mouse induced by dermatitis by applying weekly house dust mite (DPE), cut it into small pieces, add collagenase 1 mg/ml (in 2% FBS + RPMI1640), and shake at 37°C (180 rpm, 20 min) The method of recovering the supernatant after culturing in an incubator was repeated 4 times. The cultured supernatant was treated with ACK solution (8.3 g NH 4 Cl, 1 g KHCO 3 in 1 ℓ of demineralized water + 0.1 mM EDTA) at room temperature for 5 minutes to lyse red blood cells and washed twice with D-PBS again. After staining with 0.04% trypan blue, the number of cells was measured. After adjusting the measured skin tissue-infiltrating cells to 5 × 10 5 cells, immunofluorescence staining was performed at 4°C. PEanti-CD3e, FITC-anti-CD69, FITC-anti-CCR3, PE-anti-Gr-1, FITC-anti-CD11b, PE-anti-Gr-1, PE-anti-B220 and FITC-anti- IgE was added and reacted on ice for 30 minutes. After the reaction, after washing with phosphate buffered saline at least 3 times, CD3 + /CD69 + , CCR3 + , B220 + /IgE + , CD11b + /Gr-1 + After analyzing the cell number as a percentage (%), the absolute cell number in each tissue was calculated by applying the total cell number.

면역세포수를 관찰한 결과 피부에서는 정상군의 총 면역 세포수는 29 ± 2.5 (×104/g), 대조군 119.5 ± 23.5(×104/g), CsA 투여군 52.0 ± 5.0 (×104/g), ALH 5% 투여군 56.0 ± 7.0 (×104/g), ALH 1% 투여군 55 ± 8.0 (×104/g)으로 나타나 대조군에 비하여 유의성 있는 감소 효과를 나타내었다 (표 2 참조).As a result of observing the number of immune cells, the total number of immune cells in the normal group was 29 ± 2.5 (×10 4 /g), 119.5 ± 23.5 (×10 4 /g) in the control group, and 52.0 ± 5.0 (×10 4 /g) in the CsA group. g), ALH 5% administration group 56.0 ± 7.0 (×10 4 /g), ALH 1% administration group 55 ± 8.0 (×10 4 /g) showed a significant reduction effect compared to the control group (see Table 2).

피부에서의 CD3+/CD69+ 세포 수는 정상군은 2.2 ± 1.4 (×104/g), 대조군 23.0 ± 1.9 (×104/g), CsA 투여군 9.5 ± 0.5 (×104/g), ALH 5% 투여군 7.5 ± 2.9 (×104/g), ALH 1% 투여군 5.9 ± 3.5 (×104/g)으로 나타나 대조군에 비하여 유의성 있는 감소 효과를 나타내었다.The number of CD3 + /CD69 + cells in the skin was 2.2 ± 1.4 (×10 4 /g) in the normal group, 23.0 ± 1.9 (×10 4 /g) in the control group, 9.5 ± 0.5 (×10 4 /g) in the CsA-administered group, The ALH 5% administration group showed 7.5 ± 2.9 (×10 4 /g) and the ALH 1% administration group 5.9 ± 3.5 (×10 4 /g), indicating a significant reduction effect compared to the control group.

CCR3+ 세포 수는 정상군은 0.7 ± 0.3 (×104/g), 대조군 9.4 ± 0.7 (×104/g), CsA 투여군 5.3 ± 1.8 (×104/g), ALH 5% 투여군 5.4 ± 1.6 (×104/g), ALH 1% 투여군 4.4 ± 1.1 (×104/g)으로 나타나 대조군에 비하여 유의성 있는 감소 효과를 나타내었다.The number of CCR3 + cells was 0.7 ± 0.3 (×10 4 /g) in the normal group, 9.4 ± 0.7 (×10 4 /g) in the control group, 5.3 ± 1.8 (×10 4 /g) in the CsA group, and 5.4 ± in the ALH 5% group. 1.6 (×10 4 /g), 4.4 ± 1.1 (×10 4 /g) of the 1% ALH group, indicating a significant reduction effect compared to the control group.

CD11b+/Gr-1+ 세포 수는 정상군은 1.0 ± 0.8 (×104/g), 대조군 9.2 ± 0.8 (×104/g), CsA 투여군 2.2 ± 0.8(×104/g), ALH 5% 투여군 4.1 ± 1.3 (×104/g), ALH 1% 투여군 3.4 ± 1.2 (×104/g)으로 나타나 대조군에 비하여 유의성 있는 감소 효과를 나타내었다.CD11b + /Gr-1 + cell count was 1.0 ± 0.8 (×10 4 /g) in the normal group, 9.2 ± 0.8 (×10 4 /g) in the control group, 2.2 ± 0.8 (×10 4 /g) in the CsA group, ALH The 5% administration group showed 4.1 ± 1.3 (×10 4 /g), and the ALH 1% administration group showed 3.4 ± 1.2 (×10 4 /g), indicating a significant reduction effect compared to the control group.

B220+/IgE+ 세포 수는 정상군은 0.6 ± 0.3 (×104/g), 대조군 6.4 ± 0.5 (×104/g), CsA 투여군 3.3 ± 0.2(×104/g), ALH 5% 투여군 2.4 ± 0.9 (×104/g), ALH 1% 투여군 1.9 ± 1.2 (×104/g)으로 나타나 대조군에 비하여 유의성 있는 감소 효과를 나타내었다.The number of B220 + /IgE + cells was 0.6 ± 0.3 (×10 4 /g) in the normal group, 6.4 ± 0.5 (×10 4 /g) in the control group, 3.3 ± 0.2 (×10 4 /g) in the CsA group, and ALH 5% It was found to be 2.4 ± 0.9 (×10 4 /g) in the administration group and 1.9 ± 1.2 (×10 4 /g) in the ALH 1% administration group, indicating a significant reduction effect compared to the control group.

표 2. 집먼지 진드기(DPE)로 유도된 Nc/Nga 마우스 피부 면역세포수Table 2. Number of Nc/Nga Mouse Skin Immune Cells Induced by House Dust Mite (DPE)

Figure pat00002
Figure pat00002

Nc/Nga mice model followed by the administration of ALH (5%, 1%/) for 8 weeks. The mice dorsal skin were removed and skin cell absolute number were measured by analyzed by flow cytometer. Values are represented as mean ± S.E. (n=4). Statistically significant value compared with Nc/Nga-normal mice group by student's t-test (*p<0.05, **p<0.01, ***p<0.001).Nc/Nga mice model followed by the administration of ALH (5%, 1%/) for 8 weeks. The mice dorsal skin were removed and skin cell absolute number were measured by analyzed by flow cytometer. Values are represented as mean ± S.E. (n=4). Statistically significant value compared with Nc/Nga-normal mice group by student's t-test (*p<0.05, **p<0.01, ***p<0.001).

4. 사이토카인 측정4. Cytokine Measurement

염증 사이토카인 분석을 위하여 집먼지 진드기로(DPE)로 유발된 아토피 피부염(atopy dermatitis-like skin)을 일으킨 Nc/Nga마우스의 실험 종료 후에 에텔로 마취하여 심장천자법으로 채혈 후 혈청을 분리하였다. 분리된 혈청에서 IL-6와 TNF-γ 농도 측정은 효소연결 면역세포 측정장치(enzyme-linked immuno-sorbent assay, ELISA, Biosource, USA)로 생산량을 측정하였다. 각 well에 Nc/Nga 마우스의 혈청 100 ㎕ (1/100 dilution)씩 분주하고 1 시간 동안 실온에서 반응 시킨 후 2회 세척용 완충용액으로 세척하였다. HRP-conjugeted Avidin 100 ㎕를 처리하고 1 시간 실온에서 반응 시킨 후 다시 세척하였다. TMB 기질을 100 ㎕씩 분주하고 암소에서 30 분간 반응시킨 후 50 ㎕의 stop 용액을 처리하여 엘라이저(ELISA reader)를 이용하여 450 ㎚에서 흡광도를 측정하였다.For the analysis of inflammatory cytokines, Nc/Nga mice that had atopic dermatitis-like skin induced by house dust mite (DPE) were anesthetized with ether after the experiment was completed, blood was collected by cardiac puncture, and serum was separated. IL-6 and TNF-γ concentrations in the isolated serum were measured with an enzyme-linked immuno-sorbent assay (ELISA, Biosource, USA). 100 μl (1/100 dilution) of Nc/Nga mouse serum was dispensed into each well, and after reacting at room temperature for 1 hour, it was washed twice with a washing buffer. 100 μl of HRP-conjugeted Avidin was treated, reacted at room temperature for 1 hour, and washed again. 100 μl of the TMB substrate was dispensed and reacted in the dark for 30 minutes, then 50 μl of stop solution was treated, and absorbance was measured at 450 nm using an ELISA reader.

비장세포 내 사이토카인 생성량 측정은 집먼지 진드기(DPE)를 도포하여 아토피 피부염이 유발된 마우스의 비장세포 (1 × 104/well)를 anti-CD28 (1 ㎍/㎖)와 anti-CD3 (1 ㎍/㎖)로 코팅된 96-well plate에서 48시간 동안 배양하였다. 그리고 IL-4, IFN-γ를 ELISA kit법으로 측정하기 위하여 각 well에 비장세포 배양 상층액 100 ㎕씩을 분주하고 1 시간 동안 실온에서 반응시킨 후 2회 세척하고 비오틴 접합항원(biotin-conjugated antigen)을 넣어 30분간 반응시켰다. 다시 2회 완충용액으로 세척하여 HRP-conjugeted Avidin 100 ㎕를 처리하여 1 시간 실온에서 반응시킨 후 다시 세척하였다. TMB 기질을 100㎕씩 분주하고 암소에서 30 분간 반응시킨 후 100 ㎕의 stop 용액을 처리하여 엘라이저(ELISA reader)를 이용하여 450 ㎚에서 흡광도를 측정하였다.To measure the amount of cytokine production in splenocytes, the splenocytes (1 × 10 4 /well) of mice induced with atopic dermatitis by application of house dust mite (DPE) were treated with anti-CD28 (1 μg/ml) and anti-CD3 (1 μg). /ml) coated 96-well plate for 48 hours. And to measure IL-4 and IFN-γ by the ELISA kit method, 100 μl of the splenocyte culture supernatant was dispensed into each well, reacted for 1 hour at room temperature, washed twice, and biotin-conjugated antigen was added and reacted for 30 minutes. After washing twice again with buffer solution, 100 μl of HRP-conjugeted Avidin was treated, reacted at room temperature for 1 hour, and washed again. 100 μl of TMB substrate was dispensed and reacted in the dark for 30 minutes, then 100 μl of stop solution was treated, and absorbance was measured at 450 nm using an ELISA reader.

혈청내 사이토카인 생성량을 측정한 결과 IL-6 생성량은 정상군은 137.9 ± 0.1 (pg/㎖), 대조군 200.6 ± 16.9(pg/㎖), CsA 투여군 153.0 ± 3.72 (pg/㎖), ALH 5% 투여군 146.8 ± 4.23 (pg/㎖), ALH 1% 투여군 156.25 ± 2.2 (pg/㎖)으로, 대조군에 비하여 유의성 있는 감소 효과를 나타내었다.As a result of measuring the amount of cytokine production in the serum, the IL-6 production amount was 137.9 ± 0.1 (pg/ml) in the normal group, 200.6 ± 16.9 (pg/ml) in the control group, 153.0 ± 3.72 (pg/ml) in the CsA group, and 5% of ALH. The administration group was 146.8 ± 4.23 (pg/ml) and the ALH 1% administration group was 156.25 ± 2.2 (pg/ml), which showed a significant reduction effect compared to the control group.

혈중 TNF-α 생성량은 정상군은 8.2 ± 1.5 (pg/㎖), 대조군 36.3 ± 5.4 (pg/㎖), CsA 투여군 25.6 ± 3.0(pg/㎖), ALH 5% 투여군 23.2 ± 1.1 (pg/㎖), ALH 1% 투여군 19.9 ± 0.3 (pg/㎖)으로 대조군에 비하여 유의성 있는 감소 효과를 나타내었다(표 3 참조).The amount of TNF-α production in the blood was 8.2 ± 1.5 (pg/ml) in the normal group, 36.3 ± 5.4 (pg/ml) in the control group, 25.6 ± 3.0 (pg/ml) in the CsA group, and 23.2 ± 1.1 (pg/ml) in the ALH 5% group. ), 19.9 ± 0.3 (pg/ml) of the ALH 1% administration group showed a significant reduction effect compared to the control group (see Table 3).

표 3. 집먼지 진드기(DPE)로 유도된 Nc/Nga 마우스 혈청 및 비장 내 싸이토카인 생성량Table 3. Cytokine production in Nc/Nga mouse serum and spleen induced by house dust mite (DPE)

Figure pat00003
Figure pat00003

To determine amount of IL-6 and TNF-α by ELISA, blood was collected from the retro-orbital plexus under ether anesthesia and serum was obtained by 10,000 rpm centrifugation and stored at -20°C until use. Splenocytes from Nc/Nga mice, were stimulated with anti-CD3 antibodies for 48 h. The culture supernatants were assayed for IL-4 and IFN-γ by ELISA. Amount of cytokines are shown in picogram per milliliter and values are represented as mean ± S.E. (n=4). Statistically significant value compared with Nc/Nga-normal mice group by student's t-test (*p<0.05, *p<0.01, ***p<0.001).To determine amount of IL-6 and TNF-α by ELISA, blood was collected from the retro-orbital plexus under ether anesthesia and serum was obtained by 10,000 rpm centrifugation and stored at -20°C until use. Splenocytes from Nc/Nga mice, were stimulated with anti-CD3 antibodies for 48 h. The culture supernatants were assayed for IL-4 and IFN-γ by ELISA. Amount of cytokines are shown in picogram per milliliter and values are represented as mean ± S.E. (n=4). Statistically significant value compared with Nc/Nga-normal mice group by student's t-test (*p<0.05, *p<0.01, ***p<0.001).

5. 혈청 중 면역글로블린 측정5. Measurement of Immunoglobulin in Serum

혈청 중 면역글로블린 측정은 시료 투여 시점인 8주와 12주, 16주에 생쥐의 안와동맥에서 모세관(capillary tube)를 이용하여 약 100 ㎕의 혈액을 채혈한 후 원심분리기 6,500 rpm에서 20분간 원심분리한 후 30 ㎕의 혈청을 분리하였다. 엘라이저(ELISA kit)를 사용하여 혈청 내 IgE를 측정하였다. 항체를 완충 용액으로 희석하여 96-well plate에 코팅한 후 4℃에서 16시간 방치하였다. 각 well을 3회 완충 용액으로 세척한 후 혈청 (100배 희석)을 100 ㎕씩 분주하였다. 이를 1시간 동안 실온에서 반응시킨 후 완충 용액으로 2회 세척한 다음 HRPconjugated Avidin 100 ㎕를 처리하고 1 시간 실온에서 반응시킨 후 다시 세척하였다. 여기에 TMB 기질을 100㎕씩 분주하고 암소에서 30분간 반응시킨 후 50 ㎕의 stop 용액을 처리하고 엘라이저(ELISA reader)를 이용하여 450 nm에서 흡광도를 측정하였다.Immunoglobulin in serum was measured at 8, 12, and 16 weeks of sample administration, about 100 μl of blood was collected from the orbital artery of the mouse using a capillary tube, and then centrifuged at 6,500 rpm in a centrifuge for 20 minutes. After that, 30 μl of serum was isolated. IgE in serum was measured using an ELISA kit. The antibody was diluted with a buffer solution, coated on a 96-well plate, and left at 4°C for 16 hours. After washing each well with a buffer solution 3 times, 100 μl of serum (100-fold dilution) was dispensed. This was reacted at room temperature for 1 hour, washed twice with a buffer solution, treated with 100 μl of HRPconjugated Avidin, reacted at room temperature for 1 hour, and washed again. Here, 100 μl of TMB substrate was dispensed and reacted in the dark for 30 minutes, then 50 μl of stop solution was treated, and absorbance was measured at 450 nm using an ELISA reader.

총 IgG1, IgG2a, IgG2b, 그리고 IgM의 혈청내 농도 측정은 실험 종료 후에 ELISA를 사용하여 측정하였다. 각 well에 혈청 100 ㎕ (1/200 dilution)씩 분주하고, 12 시간 동안 4 ℃ 냉장실에서 방치한 후 2회 완충용액으로 세척한 다음 비오틴 접합항체(biotin-conjugated antibody)를 넣고 30분간 반응시켰다. 다시 2회 완충용액으로 세척한 다음 HRP-conjugeted Avidin 100 ㎕를 처리하고 1 시간 실온에서 반응시킨 후 다시 세척하였다. TMB 기질을 100 ㎕씩 분주하고 암소에서 30 분간 반응시킨 후 100 ㎕의 stop 용액을 처리하여 엘라이저(ELISA reader)를 이용하여 450 nm에서 흡광도를 측정하였다.Serum concentrations of total IgG1, IgG2a, IgG2b, and IgM were measured using ELISA after the end of the experiment. 100 μl (1/200 dilution) of serum was dispensed into each well, left in a refrigerator at 4° C. for 12 hours, washed twice with buffer solution, and then added with biotin-conjugated antibody and reacted for 30 minutes. After washing twice again with buffer solution, 100 μl of HRP-conjugeted Avidin was treated, reacted for 1 hour at room temperature, and washed again. 100 μl of TMB substrate was dispensed and reacted in the dark for 30 minutes, then 100 μl of stop solution was treated, and absorbance was measured at 450 nm using an ELISA reader.

혈청 IgE의 생성량 측정은 Nc/Nga 마우스의 눈에서 8주, 12주, 16주에 혈액을 채혈하여 혈청을 분리한 후 IgE 생성량을 측정하였다. 혈청 IgE 수치의 변화로 8주에서는 정상군은 492.5 ± 57.8 (ng/㎖), 대조군에서는 855.5± 68.5 (ng/㎖), CsA 투여군에서는 915.5 ± 131.0 (ng/㎖), ALH 5% 투여군에서는 947.5 ± 33.8 (ng/㎖), ALH 1% 투여군에서는 709.0 ± 83.9 (ng/㎖)로서 큰 차이가 없었으나 12주에서는 정상군은 734.4 ± 138.8 (ng/㎖), 대조군에서는 3,347.1 ± 30.5 ng/㎖), CsA 투여군에서는 3,041.5 ± 47.8 (ng/㎖), ALH 5% 투여군에서는 3,117.9 ± 82.9 (ng/㎖), ALH 1% 투여군에서는 3,180.9 ± 5.4 (ng/㎖)로서 유의성 있는 감소효과를 나타내기 시작하였고 그 효과가 16주까지 지속되었다.For measurement of serum IgE production, blood was collected from the eyes of Nc/Nga mice at 8 weeks, 12 weeks, and 16 weeks, and serum was separated, and then the IgE production amount was measured. At 8 weeks, due to the change in serum IgE level, in the normal group, 492.5 ± 57.8 (ng/ml), in the control group, 855.5± 68.5 (ng/ml), in the CsA group, 915.5 ± 131.0 (ng/ml), and in the ALH 5% group, 947.5 There was no significant difference as ± 33.8 (ng/ml) and 709.0 ± 83.9 (ng/ml) in the ALH 1% group, but at 12 weeks, 734.4 ± 138.8 (ng/ml) in the normal group and 3,347.1 ± 30.5 ng/ml in the control group. ), 3,041.5 ± 47.8 (ng/ml) in the CsA administration group, 3,117.9 ± 82.9 (ng/ml) in the ALH 5% administration group, and 3,180.9 ± 5.4 (ng/ml) in the ALH 1% administration group. and the effect lasted up to 16 weeks.

혈청 중 IgG1 생성량은 정상군은 2,645.0 ± 85.2 (㎍/㎖), 대조군은 3,774.0 ± 76.4 (㎍/㎖), CsA 투여군은 3,238.5 ± 111.4 (㎍/㎖), ALH 5% 투여군은 3,691.0 ± 130.1 (㎍/㎖), ALH 1% 투여군은 3,706.0 ± 51.1 (㎍/㎖)로 생성량에 영향을 미치지 않았다.The serum IgG1 production amount was 2,645.0 ± 85.2 (μg/ml) in the normal group, 3,774.0 ± 76.4 (μg/ml) in the control group, 3,238.5 ± 111.4 (μg/ml) in the CsA group, and 3,691.0 ± 130.1 (μg) in the ALH 5% group. /ml), ALH 1% administration group did not affect the production amount as 3,706.0 ± 51.1 (㎍ / ㎖).

IgM 혈중 농도는 정상군은 647.0 ± 30.9 (㎍/㎖), 대조군은 929.5 ± 37.6 (㎍/㎖), CsA 투여군은 458.5 ± 56.5 (㎍/㎖), ALH 5% 투여군은 714.0 ± 23.4 (㎍/㎖), ALH 1% 투여군은 680.5 ± 59.7 (㎍/㎖)로 대조군에 비하여 유의성 있는 감소 효과를 나타내었다.The IgM blood concentration was 647.0 ± 30.9 (㎍/㎖) in the normal group, 929.5 ± 37.6 (㎍/㎖) in the control group, 458.5 ± 56.5 (㎍/㎖) in the CsA group, and 714.0 ± 23.4 (㎍/㎖) in the ALH 5% group. ㎖), ALH 1% administration group showed a significant reduction effect compared to the control group at 680.5 ± 59.7 (㎍ / ㎖).

IgG2a 혈중 농도는 정상군은 1,967.5 ± 55.9 (㎍/㎖), 대조군은 2,694.5 ± 33.8 (㎍/㎖), CsA 투여군은 1,473.0 ± 70.1 (㎍/㎖), ALH 5% 투여군은 2,283.5 ± 150.6 (㎍/㎖), ALH 1% 투여군은 2,153.0 ± 118.7 (㎍/㎖)로 대조군에 비하여 유의성 있는 감소 효과를 나타내었다.The IgG2a blood concentration was 1,967.5 ± 55.9 (μg/ml) in the normal group, 2,694.5 ± 33.8 (μg/ml) in the control group, 1,473.0 ± 70.1 (μg/ml) in the CsA group, and 2,283.5 ± 150.6 (μg/ml) in the ALH 5% group. ㎖), the ALH 1% administration group showed a significant reduction effect compared to the control group to 2,153.0 ± 118.7 (㎍ / ㎖).

IgG2b 혈중 농도는 정상군은 6,968.0 ± 46.1 (㎍/㎖), 대조군은 9,284.5 ± 355.8 (㎍/㎖), CsA 투여군은 6,191.5 ± 141.1 (㎍/㎖), ALH 5% 투여군은 7,907.0 ± 94.1 (㎍/㎖), ALH 1% 투여군은 7,324.0 ± 287.6 (㎍/㎖)로 대조군에 비하여 유의성 있는 감소 효과를 나타내었다(표 4 참조).The IgG2b blood concentration was 6,968.0 ± 46.1 (μg/ml) in the normal group, 9,284.5 ± 355.8 (μg/ml) in the control group, 6,191.5 ± 141.1 (μg/ml) in the CsA group, and 7,907.0 ± 94.1 (μg/ml) in the ALH 5% group. ㎖), the ALH 1% administration group showed a significant reduction effect compared to the control group at 7,324.0 ± 287.6 (㎍ / ㎖) (see Table 4).

표 4. 집먼지 진드기(DPE)로 유도된 Nc/Nga 마우스 혈청 중 면역항체 생성량Table 4. Immune Antibody Production Amount in Nc/Nga Mouse Serum Induced by House Dust Mite (DPE)

Figure pat00004
Figure pat00004

Blood was collected from the retro-orbital plexus under ether anesthesia and heparinized immediately thereafter. The plasma samples were assayed for amount of immunoglobulines by a sandwich ELISA. Values are represented as mean ± S.E. (n=4). Statistically significant value compared with Nc/Nga-control mice group by student's t-test (*p<0.05, **p<0.01, ***p<0.001).Blood was collected from the retro-orbital plexus under ether anesthesia and heparinized immediately thereafter. The plasma samples were assayed for amount of immunoglobulines by a sandwich ELISA. Values are represented as mean ± S.E. (n=4). Statistically significant value compared with Nc/Nga-control mice group by student's t-test (*p<0.05, **p<0.01, ***p<0.001).

6. 알로에 및 황금 복합 히드로겔의 그람 양성 및 그람 음성균에 대한 항균력 측정6. Measurement of antibacterial activity against gram-positive and gram-negative bacteria of aloe and golden complex hydrogel

먼저 시험용 균을 뉴트리언트 한천(Nutrient agar) 및 구연산 디스옥시콜린한천(Desoxycholate citrate agar)배양액의 탁도가 표준탁도기준(Tubidity Standard, Transmittance 35%)과 같도록 조절하여 시험균액으로 하였다.First, the turbidity of the nutrient agar (Nutrient agar) and citrate disoxycholine agar (Desoxycholate citrate agar) culture medium was adjusted to be the same as the standard turbidity standard (Tubidity Standard, Transmittance 35%) as the test bacteria solution.

시료용액으로 알로에 및 황금 복합 히드로겔을 수욕상에서 가온하여 녹이고 멤브란필터(membrane filter) 0.2㎛를 통과시킨 후 200, 100, 50, 25, 12.5 및 6.25㎍/㎖가 되도록 2배씩 단계적으로 희석하여 각각 2㎖씩 뮬러힌 톤한천배지(Mueller Hinton agar medium) 18㎖와 잘 혼화하여 굳힌 다음, 시험균액 5㎕씩을 자동분주기로 접종하고 37℃에서 18시간 배양한 후 각 균에 대한 최소발육저지농도를 관찰하였다.As a sample solution, aloe and golden complex hydrogels were dissolved by heating in a water bath, passed through a membrane filter 0.2 μm, and then diluted two-fold to 200, 100, 50, 25, 12.5 and 6.25 μg/ml in stages. After mixing 2 ml each with 18 ml of Mueller Hinton agar medium and hardening, inoculate 5 μl of each test bacterial solution with an automatic dispenser and incubate at 37° C. for 18 hours. was observed.

따로 멸균한 시험관에 뮬러힌톤브로스(Mueller Hinton broth) 8㎖, 시험균액 1㎖, 시료용액 (1000㎍/㎖) 1㎖씩을 가하여 37℃에서 18시간 배양한 다음 600nm에서 각각의 투과도를 측정하고 다음식에 의하여 세균의 성장억제율을 산출하였다. 시료를 가하지 않고 균액만 배양시킨 것을 대조군(Control)으로 하였다.In a separately sterilized test tube, 8 ml of Mueller Hinton broth, 1 ml of test bacteria solution, and 1 ml of sample solution (1000 μg/ml) were added, incubated at 37° C. for 18 hours, and then each transmittance was measured at 600 nm. The growth inhibition rate of bacteria was calculated by food. A culture in which only the bacterial solution was cultured without adding a sample was used as a control.

Figure pat00005
Figure pat00005

알로에 및 황금 복합 히드로겔의 그람 양성 및 음성균에 대한 세균 성장 억제율을 비교해보면 황금 추출물은 황색 포도상구균, 표피 포도상구균 등 그람 양성균에서 비교적 높은 항균력을 나타내었고 그람 음성균에서는 낮은 수치를 보여주었다. 한편 히드로겔의 항균력은 그람 양성 및 음성균에 모두 항균력을 나타내었으나 그 성장억제율은 낮은 편이었다.(표 5 참조)When comparing the bacterial growth inhibition rate against gram-positive and negative bacteria of aloe and gold complex hydrogel, the golden extract showed relatively high antibacterial activity against gram-positive bacteria such as Staphylococcus aureus and Staphylococcus epidermis, and showed a low level against gram-negative bacteria. On the other hand, the antibacterial activity of the hydrogel showed antibacterial activity against both Gram-positive and negative bacteria, but the growth inhibition rate was low (see Table 5).

표 5. 그람양성 및 그람음성균에 대한 알로에 및 황금 복합 히드로겔의 항균효과(%)Table 5. Antibacterial effect (%) of aloe and gold complex hydrogel against gram-positive and gram-negative bacteria

Figure pat00006
Figure pat00006

7. 아토피 피부염 유도 및 시료처리와 NC/Nga 생쥐에 유발된 아토피 피부염 억제효과 관찰 결과7. Results of atopic dermatitis induction and sample treatment and observation of inhibitory effect on atopic dermatitis induced in NC/Nga mice

먼저 8주령 된 NC/Nga 생쥐의 목, 귀, 등 인접 부위를 깨끗하게 제모한 후 제모가 끝나면 피부의 미세 상처가 치유되도록 24시간 방치하였다.First, the neck, ears, and back of the 8-week-old NC/Nga mice were cleaned of hair removal and then left for 24 hours to heal the micro-wounds on the skin when the hair removal was finished.

그리고 4% SDS 용액 제모 부위에 spray한 후, 0.5 % Tween 20과 PBS로 배양액을 만들어 영기에 집먼지 진드기 (D. pteronyssinus)추출물(DPE, 연세대학교 미생물학교실, 서울) 항원을 넣어 만들었다. 1주일에 3번씩 8주간 10 mg/ml, 50 ㎕를 도포하였고, 실험군 ALH를 5%, 1%를 적당한 농도로 8주간 투여하였다 (8주부터 16주).And after spraying 4% SDS solution on the hair removal area, 0.5% Tween 20 and PBS were used to make a culture medium, and the house dust mite (D. pteronyssinus) extract (DPE, Yonsei University Department of Microbiology, Seoul) antigen was added to Younggi. 10 mg/ml, 50 μl was applied 3 times a week for 8 weeks, and 5% and 1% of ALH in the experimental group were administered at appropriate concentrations for 8 weeks (8 weeks to 16 weeks).

집먼지 진드기(DPE)를 도포하여 피부염이 유발된 생쥐를 3개의 그룹으로 나누고, 대조군에는 생리식염수를, 양성대조군에는 시클로스포린 A(cyclosporin A), 실험군에는 황금가수분해물을 5%, 1%의 농도로 8주간 (8주에서 16주까지) 피부에 도포 하였다. 약물 처리 4주 간격으로, 관능 평가를 실시하였는데, NC/Nga 생쥐의 피부염은 아토피성 피부염에서 일반적으로 사용되는 윌콕손방법(Wilcoxon test)을 이용하였다.The mice induced by dermatitis by applying house dust mite (DPE) were divided into three groups, with physiological saline in the control group, cyclosporin A in the positive control group, and 5% and 1% concentration of golden hydrolyzate in the experimental group. was applied to the skin for 8 weeks (8 weeks to 16 weeks). At 4 week intervals of drug treatment, sensory evaluation was performed. For the dermatitis of NC/Nga mice, the Wilcoxon method commonly used in atopic dermatitis was used.

육안 평가지수는 다음의 5가지 항목을 각각 평가한 점수의 총 합으로 나타내었다. 평가 항목은 홍반 (Erythema), 가려움과 건조 피부 (Pruritus & Dry skin), 부종과 혈종 (Edema & escoriation), 짖무름 (Erosion), 그리고 태선화 (Lichenification)로 나누었다. 이 각각의 항목은 없음 (0), 약함 (1), 중증도 (2), 심함 (3)으로 채점하였다.The visual evaluation index was expressed as the sum of the scores evaluated for each of the following five items. Evaluation items were divided into Erythema, Pruritus & Dry skin, Edema & escoriation, Erosion, and Lichenification. Each of these items was scored as none (0), weak (1), severe (2), and severe (3).

그림 1을 참조하면, NC/Nga 생쥐에 유발된 아토피 피부염 억제 효과를 관찰해보면 그림 1A는 8 주령이 된 NC/Nga 생쥐의 등 부위의 사진이며, 그림 1B는 제모한 후 DPE를 8주간 도포한 후 사진으로, 각화현상이 진행되어 피부 염증이 심하게 나타내었다. 이에 반해 양성대조군인 CSA(그림 1C)는 복강 내 주사하였고, 상당한 호전현상을 나타내었다. 실험군인 황금가수분해물은 8주간 피부에 도포(그림 1D)한 결과, 대조군에 비하여 긁는 행동이 상대적으로 감소하였고, 또한, 각화, 태선화, 피부탈락 증상, 피부염 증상 등이 현저히 호전되었음을 확인할 수 있었다.Referring to Figure 1, when observing the inhibitory effect of atopic dermatitis induced in NC/Nga mice, Figure 1A is a photograph of the back of an 8-week-old NC/Nga mouse, and Figure 1B is a photo of the back region of NC/Nga mice after hair removal for 8 weeks. In the post photograph, keratinization progressed and skin inflammation was severe. In contrast, CSA (Fig. 1C), a positive control, was injected intraperitoneally and showed significant improvement. As a result of applying the gold hydrolyzate, which is the experimental group, to the skin for 8 weeks (Fig. 1D), it was confirmed that the scratching behavior was relatively reduced compared to the control group, and also keratosis, lichenification, skin exfoliation symptoms, and dermatitis symptoms were significantly improved.

그림 1. 집먼지 진드기로 유도된 NC/Nga 마우스의 아토피 피부염에 대한 알로에 및 황금 복합물의 치료효과Figure 1. Therapeutic effect of aloe and gold complex on atopic dermatitis in NC/Nga mice induced by dust mites.

Figure pat00007
Figure pat00007

또한, 상기 표 6을 참조하면, 4주마다 피부염의 심화 정도를 관능적 방법에 의하여 측정한 결과, 대조군은 8주 2.1 ± 0.4, 12주 2.5 ± 0.16, 16주 2.6 ± 0.2, CsA는 8주 1.8 ± 0.41, 12주 1.7 ± 0.25, 16주 0.9 ± 0.4, 황금 가수분해물 5% 는 8주 1.5 ± 0.16, 12주 1.7 ± 0.3, 16주 0.8 ± 0.1,황금가수분해물 1% 는 8주 1.4 ± 0.24로, 12주 2.0 ± 0.35, 16주 1.6 ± 0.4로 12주부터 유의성 있는 감소 효과를 나타내었다.In addition, referring to Table 6, as a result of measuring the severity of dermatitis every 4 weeks by a sensory method, the control group was 2.1 ± 0.4 at 8 weeks, 2.5 ± 0.16 at 12 weeks, 2.6 ± 0.2 at 16 weeks, and CsA at 8 weeks 1.8. ± 0.41, 12 weeks 1.7 ± 0.25, 16 weeks 0.9 ± 0.4, 5% golden hydrolyzate is 8 weeks 1.5 ± 0.16, 12 weeks 1.7 ± 0.3, 16 weeks 0.8 ± 0.1, 1% golden hydrolyzate is 8 weeks 1.4 ± 0.24 , showed a significant decrease from week 12 to 2.0 ± 0.35 at 12 weeks and 1.6 ± 0.4 at 16 weeks.

표 6. 집먼지 진드기로 유도된 NC/Nga 마우스의 아토피 피부염에 대한 알로에 및 황금 복합물의 육안평가지수Table 6. Visual evaluation index of aloe and gold complex for atopic dermatitis in NC/Nga mice induced by dust mites.

Figure pat00008
Figure pat00008

Effects of ALH on clinical skin features and severity in DPE-induced dermatitis model of NC/Nga mice Clinical skin index of dermatitis was defined as the sum of the individual scores graded as 0 (none), 1 (mild), 2 (moderate) and 3 (severe) for each of five signs and symptoms (itch, erythema/hemorrhage, edema, excoriation/erosion and scaling /dryness) : Symptoms were evaluated by skin dryness, eruption and wound on the three parts of the body: ear, face and head, and back Statistically significant value compared with NC/Nga-CT mice grouup by t-test (***p<0001)Effects of ALH on clinical skin features and severity in DPE-induced dermatitis model of NC/Nga mice Clinical skin index of dermatitis was defined as the sum of the individual scores graded as 0 (none), 1 (mild), 2 (moderate) and 3 (severe) for each of five signs and symptoms (itch, erythema/hemorrhage, edema, excoriation/erosion and scaling /dryness) : Symptoms were evaluated by skin dryness, eruption and wound on the three parts of the body: ear, face and head, and back Statistically significant value compared with NC/Nga-CT mice gruup by t-test (***p<0001)

8. 아토피 피부염 유도 및 시료처리와 NC/Nga 생쥐의 피부 및 귀의 현미경관찰 결과8. Atopic dermatitis induction and sample processing and microscopic observation of skin and ears of NC/Nga mice

실험 종료 후에, 왼쪽 귀 끝부분, 등 쪽 목 부분의 피부을 떼어내어 10% 파라포름알데히드(paraformaldehyde)에서 2시간 동안 고정하였다.After the end of the experiment, the skin on the tip of the left ear and the neck on the back was removed and fixed in 10% paraformaldehyde for 2 hours.

그 조직을 파라핀으로 포맷하였고, 5μm 부분의 두께로 블록(block)을 만들었다. 조직 부분은 염증을 일으키는 표피(epidermis), 진피(dermis), 케라티노사이트(keratinocytes), 호증구(neutrophils), 에오시노필(eosinophil) 및 그 외 다른 세포와 부종을 식별하는 헤마톡실린 및 에오신(hematoxyline and eosin, H&E) 염색과 비만세포 (mast cells)를 염색하는 톨루이딘(toluidine) 염색을 시행하였다.The tissue was formatted with paraffin, and blocks were made with a thickness of 5 μm. Tissue sections are epidermis, dermis, keratinocytes, neutrophils, eosinophils, and other cells that cause inflammation and hematoxylin and eosin to identify edema (hematoxyline and eosin, H&E) staining and toluidine staining to stain mast cells were performed.

면역화학 조직염색 (immuno histochemical stain)은 블록(block)을 만들고, 여기에 랫트안티마우스(rat antimouse) CD4 mAb (RM4-5; PharMingen, San Diego, CA), 랫트안티마우스(rat anti-mouse) CCR3 mAb (53-6.7; Becton Dickinson, Mountain View, CA) 항체를 사용하였다.Immunohistochemical staining (immuno histochemical stain) made a block (block), which included rat antimouse CD4 mAb (RM4-5; PharMingen, San Diego, CA), rat anti-mouse (rat anti-mouse) CCR3 mAb (53-6.7; Becton Dickinson, Mountain View, CA) antibody was used.

조직 절편을 4μm 두께로 세절한 후 프루브온 플러스 슬라이드(probe-on plus slide, Fisher Scientific, U.S.A)에 부착시켜 건조시켰다.The tissue sections were cut to a thickness of 4 μm, and then attached to a probe-on plus slide (Fisher Scientific, U.S.A) and dried.

그리고 탈파라핀 (Deparaffinized) 후 함수시키고, 0.01M 구연산 완충액(citrate buffer pH 6.0)을 이용해 마이크로웨이브오븐(microwave oven)에 15분간 전처리 하였다.And after deparaffinization (Deparaffinized), it was pretreated in a microwave oven (microwave oven) for 15 minutes using 0.01M citrate buffer (citrate buffer pH 6.0).

조직 내 과산화효소의 작용을 억제하기 위하여 3% 과신화수소수에 10분간 처리한 후, 조직 내의 항원과 비특이적 단백결합을 억제하기 위해 정상 혈청으로 단백질을 차단시켰다. 그리고 일차 단일 항체에 1시간 동안 부착시킨 다음 완충액으로 수세하였다.After treatment in 3% hydrogen peroxidase for 10 minutes to inhibit the action of peroxidase in tissues, proteins were blocked with normal serum in order to inhibit non-specific protein binding to antigens in tissues. Then, it was attached to the primary single antibody for 1 hour and then washed with a buffer solution.

실험 종료 후 마우스의 피부와 귀의 일부를 절단한 후 헤마톡실린 및 에오신(hematoxylin and eosin) 염색과 톨루이딘(toluidine blue) 염색을 통하여 조직의 일반형태 변화와 귀의 두께를 관찰한 결과 H&E 염색을 한 대조군(그림 2 B)의 피부와 귀에서는 표피(epidermis/dermis)가 부종으로 현저하게 확장되었고, 백혈구의 침윤도 관찰되었다.After the end of the experiment, part of the skin and ears of the mice were cut, and the general shape of the tissues and the thickness of the ears were observed through hematoxylin and eosin and toluidine blue staining. As a result, the H&E-stained control group In the skin and ears of (Fig. 2B), the epidermis/dermis was markedly enlarged with edema, and infiltration of leukocytes was also observed.

이에 비해 알로에 황금 복합물 투여군 (그림 2 D)에서는 대조군에 비하여 표피의 두께가 상대적으로 줄었고, 백혈구의 침윤이 현저히 감소하여 부종이 감소됨을 알 수 있었다.On the other hand, in the group administered with aloe gold complex (Fig. 2D), the thickness of the epidermis was relatively reduced compared to the control group, and the infiltration of leukocytes was significantly reduced, thereby reducing edema.

비만세포(mast cell)를 염색하는 톨루이딘(toluidine) 염색에서는 대조군 (그림 2 F)은 진피(dermis) 주변에 비만세포 (화살표)가 많이 침윤된 것을 알 수 있다.In the toluidine staining that stains mast cells, it can be seen that the control group (Fig. 2F) had a lot of infiltrated mast cells (arrows) around the dermis.

그러나 알로에 황금 복합물 투여군 (그림 2 H)에서는 사진에서 나타난 바와 같이 대조군에 비하여 비만세포를 거의 관찰 할 수 없었다.However, almost no mast cells were observed in the Aloe golden complex administered group (Fig. 2H) compared to the control group, as shown in the photo.

또한, 400배 광학 현미경에서 화석해성 장치를 통해 귀조직의 두께를 측정한 결과, 정상군은 21.1 ± 1.4 (x10/μm), 대조군이 129.5 ± 2.5 (x10/μm), CsA는 57.4 ± 7.3 (x10/μm), 알로에 황금 복합물 5% 투여군이 37.1 ± 0.3 (x10/μm), 알로에 황금 복합물 1% 투여군이 62.2 ± 1.5 (x10/μm)로 나타나 대조군에 비하여 알로에 황금 복합물 투여군에서 귀의 두께가 유의적으로 감소하는 것으로 나타났다. (표 7 참조)In addition, as a result of measuring the thickness of ear tissue through a fossil decomposition device under a 400x optical microscope, the normal group was 21.1 ± 1.4 (x10/μm), the control group was 129.5 ± 2.5 (x10/μm), and CsA was 57.4 ± 7.3 ( x10/μm), the group administered with aloe gold complex 5% showed 37.1 ± 0.3 (x10/μm), and the group administered with 1% aloe gold complex showed 62.2 ± 1.5 (x10/μm), indicating that the ear thickness was significant in the group administered with aloe gold complex compared to the control group. appeared to decrease negatively. (See Table 7)

그림 2. 아토피 피부염으로 유도된 NC/Nga 생쥐의 피부 및 귀의 현미경 관찰 결과Figure 2. Microscopic observation of skin and ears of NC/Nga mice induced by atopic dermatitis.

EarEar

H & E toluidine blue H&E toluidine blue

Figure pat00009
Figure pat00010
Figure pat00009
Figure pat00010

SkinSkin

H & E toluidine blue H&E toluidine blue

Figure pat00011
Figure pat00012
Figure pat00011
Figure pat00012

Histologic examination of ear and skin lesion in DPE-induced dermatitis model of NC/Nga mice The animals were administrated with saline (control) or SBE for 8 weeks Ear, skin biopsy was stained with hematoxylin and eosin (H&E) and toluidine blue (A, E; normal B, F: cotrol, C, G: CsA, D, H; SBE) for examining inflammatory cells and mast cell, respectively Bright microscopy (Nikon, Japan, orignal magnification, ear x 200, skin x 400)Histologic examination of ear and skin lesion in DPE-induced dermatitis model of NC/Nga mice The animals were administrated with saline (control) or SBE for 8 weeks Ear, skin biopsy was stained with hematoxylin and eosin (H&E) and toluidine blue (A , E; normal B, F: cotrol, C, G: CsA, D, H; SBE) for examining inflammatory cells and mast cell, respectively Bright microscopy (Nikon, Japan, orignal magnification, ear x 200, skin x 400)

표 7. 아토피 피부염으로 유도된 NC/Nga 생쥐의 귀 두께 비교Table 7. Comparison of ear thickness in NC/Nga mice induced by atopic dermatitis

Figure pat00013
Figure pat00013

Ear thickness of NC/Nga mice by DPE stimulation After atopy dermatitis ear in NC/Nga mice model followedby the administration ofCsA, and Scutellariae extracts for 8 weeks (Nikon, Japan, orignal magnification, ear x 400)Ear thickness of NC/Nga mice by DPE stimulation After atopy dermatitis ear in NC/Nga mice model followed by the administration ofCsA, and Scutellariae extracts for 8 weeks (Nikon, Japan, orignal magnification, ear x 400)

Claims (5)

알로에 껍질 1.0kg을 취하고 에탄올(EtOH) 2리터(L)를 넣어 50 ~ 60℃에서 8시간동안 가끔씩 흔들어 주면서 방치하는 단계;
에탄올 추출용액을 흔들어 주면서 여과지를 사용하여 감압으로 하여 여과하고 여액을 취하여 단계;
여과한 액을 감압농축기에 넣고 50 ~ 60℃에서 일정한 조건으로 감압 농축시켜 연조엑스 상태로 만드는 단계;
베타글루코시다제(β-glucosidase) 50,000unit를 10밀리리터의 물에 녹여 연조엑스에 가하고, 40 ~ 50℃에서 8시간 동안 흔들어 주면서 반응시켜 빌효 및 가수분해시키는 단계; 로 이루어진 것을 특징으로 하는 아토피 피부염 예방 및 개선효과를 나타내는 알로에 발효 및 가수분해 추출물의 제조방법.
Taking 1.0 kg of aloe shell, adding 2 liters (L) of ethanol (EtOH), and leaving it at 50 to 60° C. for 8 hours while shaking occasionally;
Filtering the ethanol extraction solution under reduced pressure using filter paper while shaking, and taking the filtrate;
Putting the filtered solution into a vacuum concentrator and concentrating under a reduced pressure at 50 to 60° C. under constant conditions to make a soft extract;
Dissolving 50,000 units of beta-glucosidase (β-glucosidase) in 10 milliliters of water, adding it to the yeonjo extract, and reacting it with shaking at 40 to 50° C. for 8 hours to fertilize and hydrolyze; A method for producing fermented and hydrolyzed aloe extract having atopic dermatitis prevention and improvement effect, comprising:
제1항에 의해 제조된 알로에 발효 및 가수분해 추출물 100g을 취하고, 황금 가수분해 추출물 200g, 어성초 발효추출물 100g 및 알로에베라 20kg을 균일하게 혼합하여 알로에 발효 및가수분해 추출 복합물을 얻은 다음,
정제수 40kg, 글리세릴스테아레이트 6kg, 피이지100스테아레이트 4kg, 소르비탄스테아레이트 3kg, 폴리소르베이트20 3kg, 디메치콘 0.5kg, 트리에탄올아민 1kg, 카프릴릭카프릴트리글리세라이드 4kg, 카보머941 1kg, 부틸렌글라이콜 1kg, 이소도데칸 0.5kg, 글리세린 5kg, 디에칠헥실카보네이트 3kg, 디카프릴카보네이트 3kg, 스테아릴알코올 5kg, 글리세릴베헤네이트 1kg, 페녹시에탄올 0.5kg, 디스테아디모늄헥토라이트 1kg, 소르비탄세스퀴올레이이트 3kg, 메칠파라벤 0.3kg, 프로필파라벤 0.2kg, 디소디움이디티에이 0.5kg을 혼합하고 70 ~ 75℃에서 4시간 동안 가온하면서 혼합하여 바디로션 기제를 조제한 후 상기 알로에 가수분해 추출 혼합물과 함께 호모게나이저에 투입하여 3,000 ~ 3,500 알피엠으로 30분 동안 균질화시켜 바디로션을 제조하는 것을 특징으로 하는 알로에 발효 및 가수분해 추출물을 이용하여 제조된 화장품.
Take 100 g of the aloe fermentation and hydrolysis extract prepared according to claim 1, and uniformly mix 200 g of golden hydrolyzed extract, 100 g of fermented eoseongcho ferment extract and 20 kg of aloe vera to obtain an aloe fermentation and hydrolysis extraction complex,
Purified water 40kg, glyceryl stearate 6kg, PEG 100 stearate 4kg, sorbitan stearate 3kg, polysorbate 20 3kg, dimethicone 0.5kg, triethanolamine 1kg, caprylic caprylic triglyceride 4kg, carbomer 941 1kg, Butylene glycol 1kg, isododecane 0.5kg, glycerin 5kg, diethylhexyl carbonate 3kg, dicapryl carbonate 3kg, stearyl alcohol 5kg, glyceryl behenate 1kg, phenoxyethanol 0.5kg, disteadimonium hectorite 1kg , 3 kg of sorbitan sesquioleate, 0.3 kg of methylparaben, 0.2 kg of propylparaben, and 0.5 kg of disodium EDTA were mixed and heated at 70 to 75° C. for 4 hours to prepare a body lotion base, and then the aloe water Cosmetics manufactured using aloe fermentation and hydrolyzed extract, characterized in that it is put into a homogenizer together with the decomposed extraction mixture and homogenized at 3,000 to 3,500 RPM for 30 minutes to prepare a body lotion.
제1항에 의해 제조된 알로에 발효 및 가수분해 추출물 100g을 취하고, 황금 가수분해 추출물 200g, 어성초 발효추출물 100g 및 알로에베라 20kg을 균일하게 혼합하여 알로에 발효 및가수분해 추출 복합물을 얻은 다음,
정제수 50kg, 라우린산 6kg, 미리스틴산 4kg, 모노알킬포스페이트 1kg, 옥시벤존 0.5kg, 글리콜디스테아레이트 4kg, 트리에탄올아민 1kg, 폴리쿠아테니움 1kg, 라우릴설폰산트리에탄올아민 1kg, 라우라마이드 DEA 1kg, 사이클로메치콘 0.5kg, 코카미드프로필베타인 2kg, K-쿠일가수분해콜라겐 1kg, 부틸렌글라이콜 1kg, 피이지-7-글리세릴코코에이트 5kg, 글리세린 5kg, 글리세릴베헤네이트 1kg, 페녹시에탄올 1kg, 디메치콘 0.5kg, 소르비탄세스퀴올레이이트 3kg, 프로필렌카보네이트 1kg, 메칠파라벤 0.3kg, 프로필파라벤 0.2kg, 디소디움이디티에이 0.5kg을 혼합하고, 70 ~ 75℃에서 4시간 동안 가온하면서 혼합하여 바디클린저 기제를 조제한 후 상기 알로에 발효 및 가수분해 추출 복합물과 함께 호모게나이저에 투입하여 3,000 ~ 3,500 알피엠으로 30분 동안 균질화시켜 바디클린저로 제조하는 것을 특징으로 하는 알로에 발효 및 가수분해 추출물을 이용하여 제조된 화장품.
Take 100 g of the aloe fermentation and hydrolysis extract prepared according to claim 1, and uniformly mix 200 g of golden hydrolyzed extract, 100 g of fermented eoseongcho ferment extract and 20 kg of aloe vera to obtain an aloe fermentation and hydrolysis extraction complex,
Purified water 50kg, lauric acid 6kg, myristic acid 4kg, monoalkyl phosphate 1kg, oxybenzone 0.5kg, glycol distearate 4kg, triethanolamine 1kg, polyquatenium 1kg, laurylsulfonic acid triethanolamine 1kg, lauramide DEA 1 kg, cyclomethicone 0.5 kg, cocamide propyl betaine 2 kg, K-Quyl hydrolyzed collagen 1 kg, butylene glycol 1 kg, PEG-7-glyceryl cocoate 5 kg, glycerin 5 kg, glyceryl behenate 1 kg, phenoxy Siethanol 1kg, dimethicone 0.5kg, sorbitan sesquioleate 3kg, propylene carbonate 1kg, methylparaben 0.3kg, propylparaben 0.2kg, disodium EDTA 0.5kg were mixed, and at 70 ~ 75℃ for 4 hours. Aloe fermentation and hydrolysis, characterized in that after preparing a body cleanser base by mixing while warming, it is put into a homogenizer together with the aloe fermentation and hydrolysis extraction complex and homogenized at 3,000 to 3,500 rpm for 30 minutes to prepare a body cleanser Cosmetics manufactured using extracts.
제1항에 의해 제조된 알로에 발효 및 가수분해 추출물 100g을 취하고, 황금 가수분해 추출물 200g, 어성초 발효추출물 100g 및 알로에베라 20kg을 균일하게 혼합하여 알로에 발효 및 가수분해 추출 복합물을 얻은 다음,
정제수 35kg, 글리세릴스테아레이트 5kg, 피이지100스테아레이트 3kg, 소르비탄스테아레이트 4kg, 폴리소르베이트20 3kg, 디메치콘 1kg, 트리에탄올아민 1kg, 화이트비스왁스 2kg, 카보머941 1kg, 부틸렌글라이콜 0.5kg, 이소도데칸 1kg, 글리세린 5kg, 디에칠헥실카보네이트 1kg, 디카프릴카보네이트 1kg, 스테아릴알코올 4kg, 글리세릴베헤네이트 1kg, 페녹시에탄올 1kg, 디스테아디모늄헥토라이트 1kg, 소르비탄세스퀴올레이이트 2kg, 메칠파라벤 0.3kg, 프로필파라벤 0.2kg, 디소디움이디티에이 0.5kg을 혼합하고, 70 ~ 75℃에서 4시간 동안 가온하면서 혼합하여 페이셜크림 기제를 조제한 후 상기 알로에 발효 및 가수분해 추출 복합물과 함께 호모게나이저에 투입하여 3,000 ~ 3,500 알피엠으로 30분 동안 균질화시켜 페이셜크림으로 제조하는 것을 특징으로 하는 알로에 발효 및 가수분해 추출물을 이용하여 제조된 화장품.
Take 100 g of the aloe fermentation and hydrolysis extract prepared according to claim 1, and uniformly mix 200 g of golden hydrolyzed extract, 100 g of fermented eoseongcho ferment extract and 20 kg of aloe vera to obtain an aloe fermentation and hydrolysis extraction complex,
Purified water 35kg, glyceryl stearate 5kg, PEG 100 stearate 3kg, sorbitan stearate 4kg, polysorbate 20 3kg, dimethicone 1kg, triethanolamine 1kg, white beeswax 2kg, carbomer 941 1kg, butylene glycol 0.5kg, isododecane 1kg, glycerin 5kg, diethylhexyl carbonate 1kg, dicapryl carbonate 1kg, stearyl alcohol 4kg, glyceryl behenate 1kg, phenoxyethanol 1kg, disteadimonium hectorite 1kg, sorbitan sesqui 2 kg of oleate, 0.3 kg of methylparaben, 0.2 kg of propylparaben, and 0.5 kg of disodium EDTA were mixed and heated at 70 to 75° C. for 4 hours to prepare a facial cream base, followed by fermentation and hydrolysis extraction of the aloe Cosmetics manufactured using aloe fermented and hydrolyzed extract, characterized in that it is put into a homogenizer together with the complex and homogenized at 3,000 to 3,500 RPM for 30 minutes to prepare a facial cream.
제1항에 의해 제조된 알로에 발효 및 가수분해 추출물 100g을 취하고, 황금 가수분해 추출물 200g, 어성초 발효추출물 100g 및 알로에베라 20kg을 균일하게 혼합하여 알로에 발효 및가수분해 추출 복합물을 얻은 다음,
정제수 40kg, 스쿠알란 1kg, 세티아릴알코올 1kg, 마카다미아씨 오일 1kg, 포도씨 오일 0.5kg, 부틸렌글라이콜 1kg, 폴리글타믹애씨드 1kg, 글리세린 5kg, 디에칠헥실카보네이트 1kg, 디카프릴카보네이트 0.5kg, 스테아릭애씨드 3kg, 카프릴릭/카프릭 트리글리세라이드 1kg, 스테아릴알코올 1kg, 페녹시에탄올 0.5kg, 녹차씨오일 0.5kg, 아라카딜 알코올 0.4kg, 베헤닐알코올 0.3kg, 아라카딜 글루코사이드 0.3kg, 세틸팔미테이트 0.2kg, 소르비탄올리베이트 0.5kg, 소르비탄 팔미테이트 1kg, 세테아릴 올리베이트 0.5kg, 피이지-32 0.2kg, 세라마이드3 0.3kg, 디메치콘 0.5kg, 알란토인 0.2kg, 카보머 940 0.5kg 및 트리에탄올아민 0.1kg을 혼합하고, 70 ~ 75℃에서 4시간 동안 가온하면서 혼합하여 바디크림 기제를 조제한 후 상기 알로에 발효 및 가수분해 추출 복합물과 함께 호모게나이저에 투입하여 3,000 ~ 3,500 알피엠으로 30분 동안 균질화시켜 바디크림을 제조하는 것을 특징으로 하는 알로에 발효 및 가수분해 추출물을 이용하여 제조된 화장품.
Take 100 g of the aloe fermentation and hydrolysis extract prepared according to claim 1, and uniformly mix 200 g of golden hydrolyzed extract, 100 g of fermented eoseongcho ferment extract and 20 kg of aloe vera to obtain an aloe fermentation and hydrolysis extraction complex,
Purified water 40kg, squalane 1kg, cetiaryl alcohol 1kg, macadamia seed oil 1kg, grape seed oil 0.5kg, butylene glycol 1kg, polyglutamic acid 1kg, glycerin 5kg, diethylhexyl carbonate 1kg, dicapryl carbonate 0.5kg, stearic Acid 3kg, caprylic/capric triglyceride 1kg, stearyl alcohol 1kg, phenoxyethanol 0.5kg, green tea seed oil 0.5kg, aracadyl alcohol 0.4kg, behenyl alcohol 0.3kg, aracadyl glucoside 0.3kg, cetylpalmi Tate 0.2kg, sorbitan olivate 0.5kg, sorbitan palmitate 1kg, cetearyl olivate 0.5kg, PEG-32 0.2kg, ceramide 3 0.3kg, dimethicone 0.5kg, allantoin 0.2kg, carbomer 940 0.5 kg and 0.1 kg of triethanolamine are mixed and heated at 70 to 75° C. for 4 hours to prepare a body cream base, and then added to a homogenizer together with the aloe fermentation and hydrolysis extraction complex to 3,000 to 3,500 RPM Cosmetics manufactured using aloe fermented and hydrolyzed extract, characterized in that the body cream is prepared by homogenizing for minutes.
KR1020200067725A 2020-06-04 2020-06-04 Cosmetics using aloe extract effective for preventing atopic dermatitis KR20210150831A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200067725A KR20210150831A (en) 2020-06-04 2020-06-04 Cosmetics using aloe extract effective for preventing atopic dermatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200067725A KR20210150831A (en) 2020-06-04 2020-06-04 Cosmetics using aloe extract effective for preventing atopic dermatitis

Publications (1)

Publication Number Publication Date
KR20210150831A true KR20210150831A (en) 2021-12-13

Family

ID=78832065

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200067725A KR20210150831A (en) 2020-06-04 2020-06-04 Cosmetics using aloe extract effective for preventing atopic dermatitis

Country Status (1)

Country Link
KR (1) KR20210150831A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117717589A (en) * 2024-02-07 2024-03-19 四川锐雅博思科技有限公司 Aloe ferment, skin immunity micro-environment regulator containing same, preparation method and application

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117717589A (en) * 2024-02-07 2024-03-19 四川锐雅博思科技有限公司 Aloe ferment, skin immunity micro-environment regulator containing same, preparation method and application
CN117717589B (en) * 2024-02-07 2024-04-23 四川锐雅博思科技有限公司 Aloe ferment, skin immunity micro-environment regulator containing same, preparation method and application

Similar Documents

Publication Publication Date Title
KR101205097B1 (en) Preparation method of aloe fermentation and hydrolysis extract showing prevention and improvement effect of atopic dermatitis and cosmetics prepared using the same
KR100772575B1 (en) External composition for improvement of skin containing herbal extracts
JP6230788B2 (en) Natural extract-containing composition
CN108904376B (en) Traditional Chinese medicine compound fermentation liquor for cosmetics with oil control and acne removal effects and preparation and application thereof
KR101908678B1 (en) A fermented composition for improving atopic dermatitis contaning natural extract
KR20200018879A (en) Natural cosmetic formulation with excellent effect for skin-microbiome homeostasis and anti-inflammation
KR20190068361A (en) Composition comprising Plant Extract Complex for Anti-bacteria, Anti-inflammation, Anti-oxidation, Inhibiting Sebum Secretion and Improving Dermatitis
KR101226089B1 (en) Compositions for Preventing, Ameliorating, or Treating Symptom of Atopic Dermatitis
KR102002894B1 (en) Cosmetic composition containing the complex natural extracts
KR20220166642A (en) Composition for treating atopic dermatitis or strengthening skin barrier or preventing aging, comprising extract of Forsythia nakaii (Uyeki) T.B.Lee
KR101829891B1 (en) A cosmetic composition comprising osmanthus asiaticus extract and clematis apiifolia extract
KR20210150831A (en) Cosmetics using aloe extract effective for preventing atopic dermatitis
CN107669565A (en) A kind of natural antibacterial bath foam containing radix glycyrrhizae
KR20110104625A (en) Manufacturing method of golden hydrolyzed extract showing prevention and improvement effect of atopic dermatitis and cosmetics prepared using the same
KR20190093283A (en) Cosmetic composition composed of including extracts of drynaria fortunei and cosmetics using the same
Rani et al. Molsari (Mimusops elengi Linn.): A boon drug of traditional medicine
CN115429725B (en) Cosmetic composition for antioxidation, anti-inflammatory and skin tranquilization
KR102142461B1 (en) Composition for improving skin condition comprising extract of korean fir
KR20120077889A (en) Composition for prevention or treatment of atopic dermatitis comprising an extract of pine leaf or pine gnarl
KR101690012B1 (en) Composition for Treating Dermatitis Comprising Extract of Weeping Fern
KR102581166B1 (en) Cosmetic composition comprising Dendropanax morbifera Extract for improving acne skin
KR20090075950A (en) Therapeutical compositions for obstinate atopic dermatitis
KR102272237B1 (en) Composition for improved atopy skin and skin moisturizing comprising natural extract
KR101985660B1 (en) Cosmetic composition for treating acne containing mixed herbal extracts fermented with Nuruk
KR102152407B1 (en) Cosmetic composition containing phycocyanobilin and its derivative derived from spirulina